

Covidien plc
Form 10-Q
January 23, 2015

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT
OF 1934

For the Quarterly Period Ended December 26, 2014

or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT
OF 1934

001-33259

(Commission File Number)

COVIDIEN PUBLIC LIMITED COMPANY
(Exact name of registrant as specified in its charter)

Ireland
(State or other jurisdiction of
incorporation or organization)
20 On Hatch, Lower Hatch Street
Dublin 2, Ireland

Telephone: +353 1 438-1700

(Address, including zip code, and telephone number,
including area code, of registrant's principal executive offices)

98-0624794
(I.R.S. Employer
Identification No.)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act (check one):

Large accelerated filer Accelerated filer

Non-accelerated filer Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

The number of ordinary shares outstanding as of January 21, 2015 was 454,507,245.

COVIDIEN PLC
INDEX TO FORM 10-Q

| | Page |
|----------|---|
| Part I. | <u>Financial Information</u> |
| Item 1. | <u>Financial Statements</u> <u>2</u> |
| | <u>Condensed Consolidated Statements of Income (Unaudited) for the Quarters Ended December 26, 2014 and December 27, 2013</u> <u>2</u> |
| | <u>Condensed Consolidated Statements of Comprehensive Income (Unaudited) for the Quarters Ended December 26, 2014 and December 27, 2013</u> <u>3</u> |
| | <u>Condensed Consolidated Balance Sheets (Unaudited) at December 26, 2014 and September 26, 2014</u> <u>4</u> |
| | <u>Condensed Consolidated Statement of Shareholders' Equity (Unaudited) for the Quarter Ended December 26, 2014</u> <u>5</u> |
| | <u>Condensed Consolidated Statements of Cash Flows (Unaudited) for the Quarters Ended December 26, 2014 and December 27, 2013</u> <u>6</u> |
| | <u>Notes to Condensed Consolidated Financial Statements</u> <u>7</u> |
| Item 2. | <u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u> <u>29</u> |
| Item 3. | <u>Quantitative and Qualitative Disclosures About Market Risk</u> <u>40</u> |
| Item 4. | <u>Controls and Procedures</u> <u>40</u> |
| Part II. | <u>Other Information</u> |
| Item 1. | <u>Legal Proceedings</u> <u>41</u> |
| Item 1A. | <u>Risk Factors</u> <u>42</u> |
| Item 2. | <u>Unregistered Sales of Equity Securities and Use of Proceeds</u> <u>43</u> |
| Item 6. | <u>Exhibits</u> <u>43</u> |
| | <u>Signatures</u> <u>44</u> |

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

COVIDIEN PLC

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)

Quarters Ended December 26, 2014 and December 27, 2013

(in millions, except per share data)

| | Quarter Ended | |
|--|----------------------|----------------------|
| | December 26, 2014 | December 27, 2013 |
| Net sales | \$2,686 | \$2,639 |
| Cost of goods sold | 1,042 | 1,076 |
| Gross profit | 1,644 | 1,563 |
| Selling, general and administrative expenses | 865 | 850 |
| Research and development expenses | 133 | 125 |
| Restructuring (credits) charges, net | (2 |) 57 |
| Operating income | 648 | 531 |
| Interest expense | (48 |) (53 |
| Interest income | 3 | 2 |
| Other (expense) income, net | (20 |) 33 |
| Income before income taxes | 583 | 513 |
| Income tax expense | 72 | 115 |
| Net income | \$511 | \$398 |
| Net income per share: | | |
| Basic | \$1.13 | \$0.88 |
| Diluted | 1.12 | 0.87 |
| Weighted-average number of shares outstanding: | | |
| Basic | 453 | 452 |
| Diluted | 458 | 456 |
| Cash dividends declared per ordinary share | \$0.36 | \$— |

See Notes to Condensed Consolidated Financial Statements.

COVIDIEN PLC
 CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED)
 Quarters Ended December 26, 2014 and December 27, 2013
 (in millions)

| | Quarter Ended | |
|---|----------------------|----------------------|
| | December 26, 2014 | December 27, 2013 |
| Net Income | \$511 | \$398 |
| Currency translation adjustments | (120 |) (16 |
| Unrecognized (loss) gain on derivatives | (7 |) 2 |
| Unrecognized gain on investments | 5 | — |
| Unrecognized gain on benefit plans | 8 | 2 |
| Other comprehensive loss, net of income taxes | (114 |) (12 |
| Comprehensive income | \$397 | \$386 |

See Notes to Condensed Consolidated Financial Statements.

COVIDIEN PLC

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)

At December 26, 2014 and September 26, 2014

(in millions, except share data)

| | December 26, 2014 | September 26, 2014 |
|---|----------------------|-----------------------|
| Assets | | |
| Current Assets: | | |
| Cash and cash equivalents | \$1,818 | \$1,567 |
| Accounts receivable trade, less allowance for doubtful accounts of \$34 and \$35 | 1,451 | 1,532 |
| Inventories | 1,422 | 1,408 |
| Prepaid expenses and other current assets (including \$23 and \$87 due from Mallinckrodt) | 896 | 947 |
| Total current assets | 5,587 | 5,454 |
| Property, plant and equipment, net | 1,984 | 2,024 |
| Goodwill | 8,823 | 8,851 |
| Intangible assets, net | 3,209 | 3,282 |
| Due from former parent and affiliate | 272 | 280 |
| Other assets | 740 | 810 |
| Total Assets | \$20,615 | \$20,701 |
| Liabilities, Redeemable Noncontrolling Interest and Shareholders' Equity | | |
| Current Liabilities: | | |
| Current maturities of long-term debt | \$1,010 | \$1,009 |
| Accounts payable | 473 | 501 |
| Accrued and other current liabilities (including \$19 and \$81 due to Mallinckrodt) | 1,432 | 1,778 |
| Total current liabilities | 2,915 | 3,288 |
| Long-term debt | 4,051 | 4,035 |
| Income taxes payable | 974 | 987 |
| Guaranteed contingent tax liabilities | 555 | 555 |
| Other liabilities | 1,686 | 1,716 |
| Total Liabilities | 10,181 | 10,581 |
| Commitments and contingencies (note 14) | | |
| Redeemable noncontrolling interest (note 15) | 62 | 60 |
| Shareholders' Equity: | | |
| Preference shares, \$0.20 par value, 125,000,000 authorized; none issued | — | — |
| Ordinary shares, \$0.20 par value, 1,000,000,000 authorized; 456,276,132 and 453,975,935 issued | 91 | 91 |
| Ordinary shares held in treasury at cost; 2,290,723 and 2,027,594 | (164 |) (139 |
| Additional paid-in capital | 7,945 | 7,842 |
| Retained earnings | 2,469 | 2,121 |
| Accumulated other comprehensive income | 31 | 145 |
| Total Shareholders' Equity | 10,372 | 10,060 |
| Total Liabilities, Redeemable Noncontrolling Interest and Shareholders' Equity | \$20,615 | \$20,701 |
| See Notes to Condensed Consolidated Financial Statements. | | |

COVIDIEN PLC

CONDENSED CONSOLIDATED STATEMENT OF SHAREHOLDERS' EQUITY (UNAUDITED)

Quarter Ended December 26, 2014

(in millions)

| | Ordinary Shares | | Treasury Shares | | Additional Paid-In Capital | Retained Earnings | Accumulated Other Comprehensive Income | Total Shareholders' Equity |
|---|-----------------|--------------|-----------------|----------|----------------------------------|----------------------|---|----------------------------------|
| | Number | Par Value | Number | Amount | | | | |
| Balance at September 26, 2014 | 454 | \$91 | (2) | \$(139) | \$7,842 | \$2,121 | \$ 145 | \$ 10,060 |
| Net income | — | — | — | — | — | 511 | — | 511 |
| Other comprehensive loss, net of income taxes | — | — | — | — | — | — | (114) | (114) |
| Dividends declared | — | — | — | — | — | (163) | — | (163) |
| Repurchase of shares | — | — | — | (25) | — | — | — | (25) |
| Share options exercised | 1 | — | — | — | 79 | — | — | 79 |
| Vesting of restricted shares | 1 | — | — | — | — | — | — | — |
| Equity-based compensation | — | — | — | — | 24 | — | — | 24 |
| Balance at December 26, 2014 | 456 | \$91 | (2) | \$(164) | \$7,945 | \$2,469 | \$ 31 | \$ 10,372 |

See Notes to Condensed Consolidated Financial Statements.

COVIDIEN PLC
 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
 Quarters Ended December 26, 2014 and December 27, 2013
 (in millions)

| | Quarter Ended | |
|---|----------------------|----------------------|
| | December 26, 2014 | December 27, 2013 |
| Cash Flows From Operating Activities: | | |
| Net income | \$511 | \$398 |
| Adjustments to reconcile net cash provided by operating activities: | | |
| Depreciation and amortization | 150 | 134 |
| Impairment of intangible assets | — | 28 |
| Equity-based compensation | 24 | 26 |
| Deferred income taxes | 24 | 26 |
| Provision for losses on accounts receivable and inventory | 14 | 13 |
| Other non-cash items | (33) | (5) |
| Changes in assets and liabilities, net of the effects of acquisition: | | |
| Accounts receivable, net | 15 | (82) |
| Inventories | (56) | (21) |
| Accounts payable | (19) | (6) |
| Income taxes | (14) | (16) |
| Accrued and other liabilities | (287) | (238) |
| Other | 122 | (36) |
| Net cash provided by operating activities | 451 | 221 |
| Cash Flows From Investing Activities: | | |
| Capital expenditures | (60) | (61) |
| Acquisition, net of cash acquired | — | (24) |
| Other | (2) | (4) |
| Net cash used in investing activities | (62) | (89) |
| Cash Flows From Financing Activities: | | |
| Dividends paid | (163) | (145) |
| Repurchase of shares | (25) | (312) |
| Proceeds from exercise of share options | 44 | 44 |
| Other | 35 | 4 |
| Net cash used in financing activities | (109) | (409) |
| Effect of currency rate changes on cash | (29) | (10) |
| Net increase (decrease) in cash and cash equivalents | 251 | (287) |
| Cash and cash equivalents at beginning of period | 1,567 | 1,868 |
| Cash and cash equivalents at end of period | \$1,818 | \$1,581 |
| See Notes to Condensed Consolidated Financial Statements. | | |

COVIDIEN PLC
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

1. Basis of Presentation

Basis of Presentation—The accompanying financial statements reflect the consolidated operations of Covidien plc, a company incorporated in Ireland, and its subsidiaries (Covidien or the Company). The unaudited condensed consolidated financial statements have been prepared in U.S. dollars, in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP). The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make use of estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities, and the reported amounts of revenues and expenses. Actual results may differ from those estimates. In management's opinion, the unaudited condensed consolidated financial statements contain all normal recurring adjustments necessary for a fair presentation of the interim results reported. The year-end balance sheet data was derived from audited consolidated financial statements. These financial statements do not include all of the annual disclosures required by U.S. GAAP; accordingly, they should be read in conjunction with the Company's audited consolidated financial statements in its Annual Report on Form 10-K for the fiscal year ended September 26, 2014.

2. Medtronic Transaction

On January 6, 2015, shareholders of Covidien and Medtronic, Inc. approved the acquisition of Covidien by Medtronic in a cash-and-stock transaction. Each outstanding ordinary share of Covidien will be converted into the right to receive \$35.19 in cash and 0.956 of an ordinary share of Medtronic plc (a newly formed Irish company). Cash will be paid in lieu of any fractional share amounts. The consummation of the transaction is subject to approval by the Irish High Court. The Irish High Court has set January 26, 2015 to hear the Company's petition to sanction the scheme of arrangement under which Medtronic will acquire the Company. If the Irish High Court sanctions the scheme of arrangement at the January 26, 2015 hearing, the transaction is expected to close on or prior to January 29, 2015. In anticipation of the close of the transaction, on January 20, 2015, the Company canceled all of the ordinary shares that were held as treasury shares.

3. Segment and Geographic Data

The Company's reportable segments are as follows:

Medical Devices includes worldwide sales of the following products: advanced and general surgical solutions, peripheral vascular and neurovascular therapies, patient monitoring products, and airway and ventilation products. It also includes sales of the following products outside the United States: nursing care, medical surgical, SharpSafety™ and original equipment manufacturer (OEM) products.

U.S. Medical Supplies includes sales of the following products in the United States: nursing care, medical surgical, SharpSafety™ and OEM products.

The Company has aggregated the following four operating segments into the Medical Devices reportable segment based upon their similar operational and economic characteristics:

• Western Europe;

• Developed Markets—Canada, Japan, Australia and New Zealand;

• Emerging Markets—Eastern Europe, Middle East, Africa, Asia (excluding Japan) and Latin America; and

• U.S. Medical Devices.

Management measures and evaluates the Company's operating segments based on segment net sales and operating income. Management excludes certain corporate expenses from segment operating income. In addition, certain amounts that management considers to be non-recurring or non-operational are excluded from segment operating income because management evaluates the operating results of the segments excluding such items. These items include net restructuring charges and related accelerated depreciation; transaction costs associated with the Company's definitive agreement to be acquired by Medtronic; and impairments and other charges associated with certain product discontinuances. Although these amounts are excluded from segment operating income, as applicable, they are included in the reconciliations that follow.

COVIDIEN PLC
 NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
 (Unaudited)

Selected information by business segment is presented below:

| (Dollars in Millions) | Quarter Ended | | |
|---|----------------------|----------------------|---|
| | December 26, 2014 | December 27, 2013 | |
| Net sales ⁽¹⁾ : | | | |
| Medical Devices | \$2,278 | \$2,251 | |
| U.S. Medical Supplies | 408 | 388 | |
| Consolidated net sales | \$2,686 | \$2,639 | |
| Segment operating income: | | | |
| Medical Devices | \$686 | \$650 | |
| U.S. Medical Supplies | 60 | 39 | |
| Segment operating income | 746 | 689 | |
| Unallocated amounts: | | | |
| Corporate expenses | (82 |) (90 |) |
| Restructuring credits (charges), net ⁽²⁾ | 2 | (59 |) |
| Transaction costs ⁽³⁾ | (18 |) — |) |
| Renal denervation charges, net ⁽⁴⁾ | — | (9 |) |
| Interest expense, net | (45 |) (51 |) |
| Other (expense) income, net | (20 |) 33 |) |
| Income before income taxes | \$583 | \$513 | |

(1) Amounts represent sales to external customers. Intersegment sales are insignificant.

(2) Amounts include restructuring-related accelerated depreciation expense. Note 4 provides additional information regarding these amounts.

(3) Represents costs incurred in connection with the Company's pending acquisition by Medtronic, which is discussed in note 2.

Represents charges incurred in connection with the Company's decision to exit its OneShot™ renal denervation program totaling \$35 million, the majority of which relates to the write-off of completed technology, which is

(4) discussed in note 9. These charges were partially offset by income of \$26 million resulting from the reversal of contingent consideration associated with the fiscal 2012 acquisition of Maya Medical, which is discussed in note 11.

Net sales by groups of products are as follows:

| (Dollars in Millions) | Quarter Ended | |
|-----------------------|----------------------|----------------------|
| | December 26, 2014 | December 27, 2013 |
| Advanced Surgical | \$928 | \$853 |
| General Surgical | 385 | 408 |
| Surgical Solutions | 1,313 | 1,261 |
| Peripheral Vascular | 308 | 315 |
| Neurovascular | 120 | 110 |
| Vascular Therapies | 428 | 425 |
| Patient Monitoring | 251 | 250 |

Edgar Filing: Covidien plc - Form 10-Q

| | | |
|------------------------------|---------|---------|
| Airway & Ventilation | 166 | 182 |
| Nursing Care | 257 | 259 |
| Patient Care | 271 | 262 |
| Respiratory and Patient Care | 945 | 953 |
| Total Covidien | \$2,686 | \$2,639 |

8

COVIDIEN PLC
 NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
 (Unaudited)

Net sales by geographic area are as follows:

| (Dollars in Millions) | Quarter Ended | |
|---|----------------------|----------------------|
| | December 26, 2014 | December 27, 2013 |
| Net sales ⁽¹⁾ : | | |
| United States | \$1,391 | \$1,307 |
| Non-U.S. Developed Markets ⁽²⁾ | 891 | 934 |
| Emerging Markets | 404 | 398 |
| Total Covidien | \$2,686 | \$2,639 |

⁽¹⁾ Sales to external customers are based primarily on the location of the customer.

⁽²⁾ Non-U.S. Developed Markets includes Western Europe, Japan, Canada, Australia and New Zealand.

4. Restructuring (Credits) Charges, Net

In fiscal 2013, the Company launched a restructuring program designed to improve the Company's cost structure. This program includes actions across the Company's segments and corporate. Such actions include, among other things, reducing corporate expenses, expanding the use of shared services in low-cost locations, outsourcing services where appropriate, streamlining the Company's organizational structure, consolidating manufacturing locations, consolidating and optimizing distribution centers and expanding low-cost country sourcing. The Company expects to incur aggregate charges between \$350 million and \$450 million associated with these actions. These charges, which are recorded as the specific actions required to execute on these initiatives are identified and approved, are expected to be incurred through fiscal 2018. This program excludes restructuring actions associated with acquisitions.

In fiscal 2011, the Company launched a \$275 million restructuring program designed to improve the Company's cost structure. This program includes actions across the Company's segments and corporate and excludes restructuring actions associated with acquisitions. In fiscal 2013, charges totaling approximately \$50 million recorded under this program by the Company's former Pharmaceuticals segment were reclassified to discontinued operations.

Accordingly, aggregate charges of approximately \$225 million are expected to relate to the Company's continuing operations. These charges, which are recorded as the specific actions required to execute on these initiatives are identified and approved, are expected to be incurred by the end of fiscal 2015.

Net restructuring (credits) charges, including accelerated depreciation and actions associated with acquisitions, by segment were as follows:

| (Dollars in Millions) | Quarter Ended | | |
|---|----------------------|----------------------|---|
| | December 26, 2014 | December 27, 2013 | |
| Medical Devices | \$(2 |) \$56 | |
| U.S. Medical Supplies | — | 1 | |
| Corporate | — | 2 | |
| Net restructuring (credits) charges, including accelerated depreciation | (2 |) 59 | |
| Less: accelerated depreciation | — | (2 |) |
| Restructuring (credits) charges, net | \$(2 |) \$57 | |

COVIDIEN PLC
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

Net restructuring (credits) charges, including accelerated depreciation, consisted of the following:

| (Dollars in Millions) | Quarter Ended | |
|---|----------------------|----------------------|
| | December 26, 2014 | December 27, 2013 |
| Acquisition-related restructuring actions | \$2 | \$3 |
| 2013 program | (3 |) 57 |
| 2011 and prior programs | (1 |) (1 |
| Net restructuring (credits) charges, including accelerated depreciation | (2 |) 59 |
| Less: non-cash charges, including accelerated depreciation | — | (2 |
| Amount expected to be settled in cash | \$(2 |) \$57 |

The following table summarizes cash activity for restructuring reserves related to acquisitions for the quarter ended December 26, 2014:

| (Dollars in Millions) | Employee | | |
|-------------------------------|---------------------------|-------|-------|
| | Severance and Benefits | Other | Total |
| Balance at September 26, 2014 | \$9 | \$15 | \$24 |
| Charges | — | 2 | 2 |
| Cash payments | (3 |) (3 |) (6 |
| Balance at December 26, 2014 | \$6 | \$14 | \$20 |

The following table summarizes cash activity for restructuring reserves related to the 2013 and 2011 and prior programs for the quarter ended December 26, 2014, substantially all of which relates to employee severance and benefits:

| (Dollars in Millions) | 2013 Program | 2011 and Prior Programs | Total |
|-------------------------------|--------------|----------------------------|-------|
| Balance at September 26, 2014 | \$57 | \$38 | \$95 |
| Charges | 3 | — | 3 |
| Changes in estimate | (5 |) (2 |) (7 |
| Cash payments | (7 |) (4 |) (11 |
| Currency translation | (2 |) (1 |) (3 |
| Balance at December 26, 2014 | \$46 | \$31 | \$77 |

Net restructuring and related charges, including associated asset impairments, incurred cumulative to date under the 2013 and 2011 programs as of December 26, 2014 were as follows:

| (Dollars in Millions) | 2013 Program | 2011 Program |
|-----------------------|--------------|--------------|
| Medical Devices | \$88 | \$158 |
| U.S. Medical Supplies | 23 | 14 |
| Corporate | 13 | 11 |
| Total | \$124 | \$183 |

Restructuring reserves were reported on the Company's condensed consolidated balance sheets as follows:

| (Dollars in Millions) | December 26, 2014 | September 26, 2014 |
|---------------------------------------|----------------------|-----------------------|
| Accrued and other current liabilities | \$67 | \$86 |
| Other liabilities | 30 | 33 |
| Restructuring reserves | \$97 | \$119 |

COVIDIEN PLC
 NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
 (Unaudited)

5. Retirement Plans

The net periodic benefit cost for the Company's defined benefit pension plans was as follows:

| (Dollars in Millions) | Quarter Ended | |
|------------------------------------|----------------------|----------------------|
| | December 26, 2014 | December 27, 2013 |
| Service cost | \$4 | \$4 |
| Interest cost | 5 | 5 |
| Expected return on plan assets | (6 |) (5 |
| Amortization of net actuarial loss | 3 | 2 |
| Net periodic benefit cost | \$6 | \$6 |

The net periodic benefit cost for postretirement benefit plans for the quarters ended December 26, 2014 and December 27, 2013 was insignificant.

6. Other (Expense) Income, Net

Other (expense) income, net consisted of the following:

| (Dollars in Millions) | Quarter Ended | |
|--|----------------------|----------------------|
| | December 26, 2014 | December 27, 2013 |
| (Loss) income under Tyco tax sharing agreement (note 12) | \$(11 |) \$32 |
| Net foreign currency loss | (7 |) — |
| (Loss) gain on investments, net | (2 |) 1 |
| Other (expense) income, net | \$(20 |) \$33 |

(Loss) income under Tyco tax sharing agreement represents a decrease or increase to the receivable from Tyco International plc and TE Connectivity Ltd. and primarily reflects 58% of the interest and other income taxes payable amounts released or recorded during each period that are subject to the Tyco tax sharing agreement. Income under the Tyco tax sharing agreement for the quarter ended December 27, 2013 also includes \$25 million of income for Covidien's portion of Tyco International's settlement of contract claims under a 2002 tax agreement with CIT Group Inc., a former subsidiary of Tyco International.

During the first quarter of fiscal 2015, the Company began including net gains and losses on foreign exchange transactions and related gains and losses on associated hedge transactions in other (expense) income, net. These amounts had previously been included in costs of goods sold, to the extent they related to inventory transactions, or in selling, general and administrative expenses. The comparative prior period amounts, which are presented in note 10, have not been reclassified to other (expense) income, net as the amounts were insignificant.

7. Earnings per Share

The weighted-average ordinary shares used in the computations of basic and diluted earnings per share were as follows:

| (in Millions) | Quarter Ended | |
|---|----------------------|----------------------|
| | December 26, 2014 | December 27, 2013 |
| Basic shares | 453 | 452 |
| Effect of share options and restricted shares | 5 | 4 |
| Diluted shares | 458 | 456 |

The computation of diluted earnings per share for the quarter ended December 26, 2014 excludes an insignificant amount of restricted share units because the performance criteria related to the units had not yet been met. The computation of diluted earnings per share for the quarter ended December 27, 2013 excludes approximately 4 million of options and restricted share

COVIDIEN PLC
 NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
 (Unaudited)

units because either the effect would have been anti-dilutive or the performance criteria related to the units had not yet been met.

8. Inventories

At the end of each period, inventories were comprised of the following:

| (Dollars in Millions) | December 26, 2014 | September 26, 2014 |
|--|----------------------|-----------------------|
| Purchased materials and manufactured parts | \$335 | \$319 |
| Work in process | 178 | 170 |
| Finished goods | 909 | 919 |
| Inventories | \$1,422 | \$1,408 |

9. Goodwill and Intangible Assets

The changes in the carrying amounts of goodwill for the quarter ended December 26, 2014 were as follows:

| (Dollars in Millions) | Medical Devices | U.S. Medical Supplies | Total |
|--------------------------------|--------------------|--------------------------|---------|
| Goodwill at September 26, 2014 | \$8,488 | \$363 | \$8,851 |
| Currency translation | (28 |) — | (28 |
| Goodwill at December 26, 2014 | \$8,460 | \$363 | \$8,823 |

The gross carrying amount and accumulated amortization of intangible assets at the end of each period were as follows:

| (Dollars in Millions) | December 26, 2014 | | September 26, 2014 | |
|-------------------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|
| | Gross Carrying Amount | Accumulated Amortization | Gross Carrying Amount | Accumulated Amortization |
| Amortizable: | | | | |
| Completed technology | \$2,432 | \$972 | \$2,427 | \$938 |
| Customer relationships | 1,435 | 305 | 1,437 | 285 |
| Other | 137 | 89 | 140 | 89 |
| Total | \$4,004 | \$1,366 | \$4,004 | \$1,312 |
| Non-Amortizable: | | | | |
| Trademarks | \$317 | | \$319 | |
| In-process research and development | 254 | | 271 | |
| Total | \$571 | | \$590 | |

In connection with management's regular review of strategic programs and growth potential for the Company's product portfolio, management decided to exit the Company's OneShot™ renal denervation program. This decision was primarily driven by slower than expected development of the renal denervation market. As a result of this decision, during the first quarter of fiscal 2014, the Company recorded pre-tax intangible asset impairment charges of \$28 million to write off the completed technology associated with this project. These charges were included in selling, general and administrative expenses.

COVIDIEN PLC
 NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
 (Unaudited)

Intangible asset amortization expense was \$65 million and \$53 million for the quarters ended December 26, 2014 and December 27, 2013, respectively. Annual amortization expense associated with the intangible assets included on the Company's balance sheet as of December 26, 2014 is expected to be as follows:

(Dollars in Millions)

| | |
|-------------|-------|
| Fiscal 2015 | \$260 |
| Fiscal 2016 | 254 |
| Fiscal 2017 | 251 |
| Fiscal 2018 | 247 |
| Fiscal 2019 | 242 |

10. Derivative Instruments

The Company is exposed to certain risks relating to its business operations. Risks that relate to interest rate exposure, foreign exchange exposure and certain commodity price exposures are managed by using derivative instruments. The Company uses interest rate swaps to manage interest rate exposure. Foreign currency exchange option and forward contracts are used to economically manage the foreign exchange exposures of operations outside the United States. In addition, the Company may use cross currency interest rate swaps to manage currency risk related to certain debt. Swap contracts on commodities are periodically entered into to manage the price risk associated with forecasted purchases of commodities used in the Company's manufacturing processes.

The Company recognizes all derivative instruments as either assets or liabilities at fair value on the condensed consolidated balance sheet. Changes in a derivative financial instrument's fair value are recognized in earnings unless specific hedge criteria are met. The Company has designated its interest rate lock contracts and commodity swap contracts as cash flow hedges and its interest rate swap contracts as fair value hedges. The Company has not designated the foreign currency exchange forward and option contracts, nor the cross currency interest rate swap, as hedging instruments.

Interest Rate Exposure

Fair Value Hedges—The Company manages interest rate exposure through the use of interest rate swap transactions with financial institutions acting as principal counterparties to convert a portion of fixed-rate debt to variable-rate debt. These transactions are designated as fair value hedges.

During the third quarter of fiscal 2014, CIFSA entered into interest rate swaps on \$500 million principal amount of its 3.20% senior notes due 2022 and \$500 million principal amount of its 2.95% senior notes due 2023. Under these contracts, the Company receives fixed amounts of interest applicable to the underlying notes and pays a floating amount based upon the three-month U.S. dollar LIBOR, plus a margin. During the quarter ended December 26, 2014, the Company recognized an \$18 million loss on the hedged fixed-rate debt attributable to changes in the market interest rates and an offsetting \$18 million gain on the related interest rate swaps, both of which were included in interest expense. These swaps were terminated subsequent to the end of the quarter, resulting in a \$48 million gain that will be amortized to interest expense over the remaining life of the related debt.

During fiscal 2011, CIFSA entered into and subsequently terminated interest rate swaps that converted its senior notes due in 2017 from fixed-rate debt to variable-rate debt. Since the interest rate swaps were designated as hedging instruments of outstanding debt, the \$23 million gain is being amortized to interest expense over the remaining life of the related debt.

Cash Flow Hedges—During both fiscal 2013 and 2007, CIFSA entered into forward interest rate lock contracts to hedge the risk of variability in market interest rates prior to the issuance of fixed-rate senior notes. The rate locks were designated as cash flow hedges at inception and were terminated prior to the issuance of the notes in accordance with their terms. The rate locks were considered to be highly effective; accordingly, the gains and losses that resulted upon termination of the rate locks were recorded in accumulated other comprehensive income and are being amortized to interest expense over the terms of the notes. The amounts reclassified to earnings during the quarters ended December 26, 2014 and December 27, 2013 were insignificant, as is the amount expected to be reclassified to

earnings during the next 12 months. At December 26, 2014 and September 26, 2014, the amount of loss that remained in accumulated other comprehensive income was \$31 million and \$32 million, respectively.

COVIDIEN PLC
 NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
 (Unaudited)

Foreign Exchange Exposure

Derivatives not Designated as Hedging Instruments—The Company's operations outside the United States are significant. As a result, the Company has foreign exchange exposure on the translation of the financial statements and on transactions denominated in foreign currencies. The Company's policy is to use various forward and option contracts to economically manage foreign currency exposures on accounts and notes receivable, accounts payable, intercompany loans and forecasted transactions that are denominated in certain foreign currencies, principally the euro, as well as approximately 20 other currencies. The Company generally manages its exposure for forecasted transactions for the upcoming 12 months. All forward and option contracts are recorded on the condensed consolidated balance sheet at fair value. At December 26, 2014, the Company had foreign currency exchange forward and option contracts outstanding with a notional amount of \$1.384 billion. These contracts do not meet the necessary criteria to qualify for hedge accounting; accordingly, changes in fair value are recognized in earnings.

As discussed in note 6, during fiscal 2015, the Company began including the net gains and losses on foreign exchange transactions and the related net gains and losses on associated hedge transactions in other (expense) income, net. Net losses and gains from foreign currency transaction exposures and the impact of related derivatives not designated as hedging instruments were as follows:

| (Dollars in Millions) | Quarter Ended | |
|--|----------------------|----------------------|
| | December 26, 2014 | December 27, 2013 |
| Cost of goods sold: | | |
| Loss on foreign currency transaction exposures | \$— | \$(29) |
| Gain on foreign currency exchange contracts | — | 6 |
| Net foreign currency loss | \$— | \$(23) |
| Selling, general and administrative expenses: | | |
| Loss on foreign currency transaction exposures | \$— | \$(13) |
| Gain on foreign currency exchange contracts | — | 18 |
| Net foreign currency gain | \$— | \$5 |
| Other (expense) income, net: | | |
| Loss on foreign currency transaction exposures | \$(30) | \$— |
| Gain on foreign currency exchange contracts | 23 | — |
| Net foreign currency loss | \$(7) | \$— |
| Total: | | |
| Loss on foreign currency transaction exposures | \$(30) | \$(42) |
| Gain on foreign currency exchange contracts | 23 | 24 |
| Net foreign currency loss | \$(7) | \$(18) |

COVIDIEN PLC
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

Fair Value of Derivative Instruments

The following table summarizes the classification and fair values of derivative instruments reported in the condensed consolidated balance sheets:

| (Dollars in Millions) | Balance Sheet Location | December 26, 2014 | | September 26, 2014 | |
|---|---|---------------------------------|--------------------------------------|---------------------------------|--------------------------------------|
| | | Fair Value of Derivative Assets | Fair Value of Derivative Liabilities | Fair Value of Derivative Assets | Fair Value of Derivative Liabilities |
| Derivatives designated as hedging instruments: | | | | | |
| Interest rate swaps | Other assets | \$28 | \$— | \$10 | \$— |
| Derivatives not designated as hedging instruments: | | | | | |
| Foreign currency exchange contracts | Prepaid expenses and other current assets | \$98 | \$10 | \$66 | \$6 |
| Foreign currency exchange contracts | Accrued and other current liabilities | 3 | 18 | 2 | 10 |
| Total derivatives not designated as hedging instruments | | \$101 | \$28 | \$68 | \$16 |
| Total derivative instruments | | \$129 | \$28 | \$78 | \$16 |

The Company's derivatives that are subject to master netting agreements, allowing for the right of offset by the counterparty, are presented on a net basis on the condensed consolidated balance sheets. The following table provides information on all of the Company's derivative positions on a gross basis, as well as on a net basis when subject to master netting agreements, at the end of each period:

| (Dollars in Millions) | December 26, 2014 | | September 26, 2014 | |
|--|-------------------|-----------|--------------------|-----------|
| | Asset | Liability | Asset | Liability |
| Gross amounts recognized | \$129 | \$28 | \$78 | \$16 |
| Gross amounts offset in the consolidated balance sheets | (13) | (13) | (8) | (8) |
| Net amounts presented in the consolidated balance sheets | \$116 | \$15 | \$70 | \$8 |

11. Financial Instruments and Fair Value Measurements

Fair value is defined as the exit price that would be received from the sale of an asset or paid to transfer a liability, using assumptions that market participants would use in pricing an asset or liability. The fair value guidance establishes the following three-level hierarchy used for measuring fair value:

Level 1—observable inputs, such as quoted prices in active markets for identical assets or liabilities;

Level 2—significant other observable inputs that are observable either directly or indirectly; and

Level 3—significant unobservable inputs for which there is little or no market data, which requires the Company to develop its own assumptions.

COVIDIEN PLC
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

The following tables provide a summary of the significant assets and liabilities that are measured at fair value on a recurring basis at December 26, 2014 and September 26, 2014:

| (Dollars in Millions) | December 26, 2014 | Basis of Fair Value Measurement | | |
|--------------------------------------|----------------------|--|---|--|
| | | Quoted Prices in Active Markets for Identical Assets (Level 1) | Significant Other Observable Inputs (Level 2) | Significant Unobservable Inputs (Level 3) |
| Assets: | | | | |
| Foreign currency exchange contracts | \$101 | \$— | \$101 | \$— |
| Interest rate swaps | 28 | — | 28 | — |
| Total assets at fair value | \$129 | \$— | \$129 | \$— |
| Liabilities: | | | | |
| Foreign currency exchange contracts | \$28 | \$— | \$28 | \$— |
| Deferred compensation liabilities | 150 | — | 150 | — |
| Contingent consideration liabilities | 230 | — | — | 230 |
| Total liabilities at fair value | \$408 | \$— | \$178 | \$230 |

| (Dollars in Millions) | September 26, 2014 | Basis of Fair Value Measurement | | |
|--------------------------------------|-----------------------|--|---|--|
| | | Quoted Prices in Active Markets for Identical Assets (Level 1) | Significant Other Observable Inputs (Level 2) | Significant Unobservable Inputs (Level 3) |
| Assets: | | | | |
| Foreign currency exchange contracts | \$68 | \$— | \$68 | \$— |
| Interest rate swaps | 10 | — | 10 | — |
| Total assets at fair value | \$78 | \$— | \$78 | \$— |
| Liabilities: | | | | |
| Foreign currency exchange contracts | \$16 | \$— | \$16 | \$— |
| Deferred compensation liabilities | 132 | — | 132 | — |
| Contingent consideration liabilities | 236 | — | — | 236 |
| Total liabilities at fair value | \$384 | \$— | \$148 | \$236 |

Foreign currency exchange contracts—The fair value of foreign currency exchange contracts was measured using significant other observable inputs and valued by reference to over-the-counter quoted market prices for similar instruments. The Company does not believe that the fair value of these derivative instruments differs significantly from the amount that could be realized upon settlement or maturity, or that the changes in fair value will have a significant effect on its results of operations, financial condition or cash flows.

Interest rate swaps—The fair value of interest rate swaps was measured using the present value of expected future cash flows using market-based observable inputs, including credit risk and interest rate yield curves. The Company does not believe that the fair value of these derivative instruments differs significantly from the amount that could be realized upon settlement or maturity, or that the changes in fair value will have a significant effect on its results of operations, financial condition or cash flows.

Deferred compensation liabilities—The Company maintains a non-qualified deferred compensation plan in the United States, which permits eligible employees to defer a portion of their compensation. A recordkeeping account is set up for each participant and the participant chooses from a variety of funds for the deemed investment of their accounts. The measurement funds generally correspond to the funds offered in the Company's U.S. tax-qualified retirement plan

and the account balance fluctuates with the investment returns on those funds.

Contingent consideration liabilities—The fair value of contingent consideration liabilities was based on significant unobservable inputs, including management estimates and assumptions, and was measured based on the probability-weighted present value of the payments expected to be made. Accordingly, the fair value of contingent consideration has been classified

COVIDIEN PLC
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

as level 3 within the fair value hierarchy. The recurring level 3 fair value measurements of contingent consideration liabilities include the following significant unobservable inputs:

| (Dollars in Millions) | Fair Value at | | Unobservable Input | Range |
|---------------------------|-------------------|----------------------|---------------------------|-------------|
| | December 26, 2014 | Valuation Technique | | |
| Revenue-based payments | \$83 | Discounted cash flow | Discount rate | 0% – 23% |
| | | | Probability of payment | 75% – 100% |
| | | | Projected year of payment | 2015 – 2024 |
| Regulatory-based payments | \$147 | Discounted cash flow | Discount rate | 0.7% – 2.5% |
| | | | Probability of payment | 80% – 95% |
| | | | Projected year of payment | 2015 – 2020 |

As of December 26, 2014, the maximum potential contingent consideration that the Company could be required to pay is \$515 million. The fair value of contingent consideration associated with acquisitions was \$230 million and \$236 million at December 26, 2014 and September 26, 2014, respectively. As of December 26, 2014, \$92 million was included in accrued and other current liabilities and \$138 million was included in other liabilities on the condensed consolidated balance sheet.

Reconciliations of the change in the fair value of contingent consideration liabilities are included in the following table:

| (Dollars in Millions) | Quarter Ended | |
|---|-------------------|-------------------|
| | December 26, 2014 | December 27, 2013 |
| Balance at beginning of period | \$236 | \$127 |
| Acquisition date fair value of contingent consideration | — | 11 |
| Change in fair value included in selling, general and administrative expenses | — | (26 |
| Payments | (6 |) — |
| Balance at end of period | \$230 | \$112 |

During the first quarter of fiscal 2014, the Company determined that the post-market clinical trial associated with the radiofrequency energy-based renal denervation device (RF Device) to treat hypertension would not be successfully completed within the required timeframe. Accordingly, the Company reversed a \$20 million contingent consideration liability associated with the achievement of this milestone. In addition, as a result of the Company's decision to exit the renal denervation program, the Company reversed \$6 million of contingent consideration liabilities that were primarily associated with the achievement of revenue targets for the RF Device. Accordingly, during the first quarter of fiscal 2014, the Company recorded income totaling \$26 million related to a reduction in the fair value of contingent consideration liabilities associated with the fiscal 2012 acquisition of Maya Medical.

Financial Instruments Not Measured at Fair Value

The fair value of cash and cash equivalents approximate carrying value since cash equivalents consist of liquid investments with a maturity of three months or less (level 1). The fair value of long-term debt, including both current and non-current maturities, is based upon quoted prices in active markets for similar instruments (level 2) and was approximately \$5.482 billion and \$5.490 billion at December 26, 2014 and September 26, 2014, respectively. It is not practicable to estimate the fair value of the Company's guaranteed contingent tax liabilities and the related amount due from former parent and affiliate.

Concentration of Credit Risk

Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash and cash equivalents, derivative financial instruments and accounts receivable. The Company invests its excess cash in deposits or money market funds and diversifies the concentration of cash among different financial institutions that have at least an A- credit rating. Counterparties to the Company's derivative financial instruments are limited to major

financial institutions with at least a Standard & Poor's and Moody's long-term debt rating of A-/A3. While the Company does not require collateral or other security to be furnished by the counterparties to its derivative financial instruments, it minimizes exposure to credit risk by dealing with a diversified group of major financial institutions and actively monitoring outstanding positions.

COVIDIEN PLC
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

Concentrations of credit risk with respect to trade accounts receivable are generally limited due to the Company's large number of customers and their diversity across many geographic areas. A portion of the Company's trade accounts receivable outside the United States, however, include sales to government-owned or supported healthcare systems in several countries that are subject to payment delays, particularly in Spain and Italy. Payment is dependent upon the financial stability of those countries' national economies and the creditworthiness of those countries' national governments. The Company routinely evaluates all government receivables for potential collection risks associated with the availability of government funding and reimbursement practices. The Company believes the current reserves related to these receivables are adequate and that this concentration of credit risk will not have a material adverse impact on the Company's financial position or liquidity.

The Company's aggregate accounts receivable, net of the allowance for doubtful accounts, in Spain and Italy at December 26, 2014 were \$262 million, of which \$15 million were over 365 days past due. At September 26, 2014, accounts receivable, net in Spain and Italy were \$256 million, of which \$16 million were over 365 days past due.

12. Transactions with Former Parent and Affiliate

Tyco Tax Sharing Agreement—On June 29, 2007, the Company entered into a tax sharing agreement, under which the Company shares responsibility for certain of its, Tyco International's and TE Connectivity's income tax liabilities for periods prior to the separation from Tyco International in 2007 (the 2007 separation). Covidien, Tyco International and TE Connectivity share 42%, 27% and 31%, respectively, of U.S. income tax liabilities that arise from adjustments made by tax authorities to its, Tyco International's and TE Connectivity's U.S. income tax returns, certain income tax liabilities arising from adjustments made by tax authorities to intercompany transactions or similar adjustments, and certain taxes attributable to internal transactions undertaken in anticipation of the 2007 separation. If Tyco International and TE Connectivity default on their obligations to Covidien under the Tyco tax sharing agreement, Covidien would be liable for the entire amount of these liabilities. All costs and expenses associated with the management of these tax liabilities are being shared equally among the parties.

At December 26, 2014, the Company is the primary obligor to the taxing authorities for \$1.007 billion of tax liabilities that are recorded on the condensed consolidated balance sheet, of which \$646 million relates to periods prior to the 2007 separation and is shared with Tyco International and TE Connectivity pursuant to the Tyco tax sharing agreement.

Income Tax Receivables—The Company has current and non-current receivables from Tyco International and TE Connectivity totaling \$286 million and \$296 million at December 26, 2014 and September 26, 2014, respectively. These receivables primarily reflect 58% of the contingent tax liabilities that are subject to the Tyco tax sharing agreement and are classified as due from former parent and affiliate on the condensed consolidated balance sheets. As discussed in note 6, adjustments to these receivables are recorded in other income, net.

Guaranteed Contingent Tax Liabilities—The Company has current and non-current liabilities for guarantee commitments and indemnifications with Tyco International and TE Connectivity related to certain contingent tax liabilities. These liabilities totaled \$577 million at both December 26, 2014 and September 26, 2014. The non-current portion of these liabilities are classified as guaranteed contingent tax liabilities on the condensed consolidated balance sheets, while the current portion is included in accrued and other current liabilities.

13. Guarantees

In connection with the 2013 separation, Mallinckrodt assumed the tax liabilities that are attributable to its subsidiaries, which amounted to approximately \$160 million. Covidien has indemnified Mallinckrodt to the extent that such tax liabilities arising from periods prior to fiscal 2013 exceed \$200 million, net of certain tax benefits realized. In addition, in connection with the 2013 separation, the Company entered into certain other guarantee commitments and indemnifications with Mallinckrodt. The values attributable to the tax indemnification and other guarantees were insignificant. Additionally, in connection with the 2007 separation, the Company entered into certain guarantee commitments and indemnifications with Tyco International and TE Connectivity, which are discussed in note 12.

In disposing of assets or businesses, the Company often provides representations, warranties and indemnities to cover various risks and liabilities, including unknown damage to the assets, environmental risks involved in the sale of real estate, liability to investigate and remediate environmental contamination at waste disposal sites and manufacturing facilities, and unidentified tax liabilities related to periods prior to disposition. The Company does not have the ability to estimate the potential liability from such indemnities because they relate to unknown conditions. However, the Company has no reason to

COVIDIEN PLC
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

believe that these uncertainties would have a material adverse effect on its results of operations, financial condition or cash flows.

The Company has recorded liabilities for known indemnification obligations included as part of environmental liabilities, which are discussed in note 14. In addition, the Company is liable for product performance; however, in the opinion of management, such obligations will not significantly affect the Company's results of operations, financial condition or cash flows.

As of December 26, 2014, the Company had various outstanding letters of credit and guarantee and surety bonds totaling \$207 million, none of which were individually significant.

14. Commitments and Contingencies

The Company is subject to various legal proceedings and claims, including patent infringement claims, products liability matters, environmental matters, employment disputes, contractual disputes and other commercial disputes. Management believes that these legal proceedings and claims likely will be resolved over an extended period of time. Although it is not feasible to predict the outcome of these proceedings, based upon the Company's experience, current information and applicable law, management does not expect these proceedings to have a material adverse effect on the Company's financial condition. However, one or more of the proceedings could have a material adverse effect on the Company's results of operations or cash flows for a future period. The significant matters are discussed below.

Legal Proceedings

The Company records a liability when a loss is considered probable and the amount can be reasonably estimated. When the reasonable estimate of a probable loss is a range and a best estimate cannot be made, the minimum amount of the range is accrued. If a loss is not probable or a probable loss cannot be reasonably estimated, no liability is recorded. As of December 26, 2014 and September 26, 2014, the Company had accruals for products liability and other legal matters totaling \$323 million and \$321 million, respectively, substantially all of which were included in other liabilities on the condensed consolidated balance sheets. These accruals include reserves for certain of the matters discussed below. In addition, as of December 26, 2014 and September 26, 2014, the Company had related insurance receivables of \$28 million and \$29 million, respectively.

Products Liability Litigation—The Company currently is involved in litigation in various state and federal courts against manufacturers of pelvic mesh products alleging personal injuries resulting from the implantation of those products. Two subsidiaries of the Company have supplied pelvic mesh products to one of the manufacturers named in the litigation and the Company is indemnifying that manufacturer on certain claims. In addition, the Company believes that this manufacturer has an obligation to indemnify the Company with respect to the promotion of the pelvic mesh products. The litigation includes a federal multi-district litigation in the United States District Court for the Northern District of West Virginia and cases in various state courts and jurisdictions outside the United States. Generally, complaints allege design and manufacturing claims, failure to warn, breach of warranty, fraud, violations of state consumer protection laws and loss of consortium claims. The Company believes that it has meritorious defenses to these claims and is vigorously defending against them. As of December 26, 2014, there were approximately 7,500 cases pending believed to involve products manufactured by Company subsidiaries. Based on current information, the Company believes that it has adequate amounts recorded relating to these matters. While the Company believes that the final disposition of all known claims, after taking into account amounts already accrued and insurance coverage, will not have a material adverse effect on the Company's results of operations, financial condition or cash flows, it is not possible at this time to determine with certainty the ultimate outcome of these matters or the effect of potential future claims.

Patent Litigation—On March 28, 2013, the federal court ruled in favor of Covidien in a patent infringement suit against Ethicon Endo-Surgery, Inc. (Ethicon), a Johnson & Johnson company, relating to Ethicon's Harmoni® line of ultrasonic surgical products. The federal court awarded Covidien \$177 million in damages upon ruling that several of Covidien's patents were valid, enforceable and infringed by Ethicon. Ethicon appealed the decision; accordingly, the Company did not record any income related to this case. In addition, on June 24, 2014, Covidien filed a lawsuit in the

U.S. District Court for the District of Connecticut against Ethicon alleging that Ethicon's ultrasonic surgical product, the Harmonic ACE[®]+7, infringes three of the Company's patents. Covidien asked the court to enjoin Ethicon from continuing to make and sell the Harmonic ACE[®]+7 device and to grant damages for the patent infringement. On October 17, 2014, the district court granted a preliminary injunction against Ethicon, which prevents Ethicon from making and selling the Harmonic ACE[®]+7 device. Ethicon obtained a temporary stay and appealed this preliminary injunction ruling. On December 4, 2014, the U.S. Court of Appeals for the Federal Circuit reversed the \$177 million judgment against Ethicon and ruled that the infringed patent claims were invalid. This ruling may

COVIDIEN PLC
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

adversely affect Covidien's ability to proceed further with the patent infringement lawsuit regarding Ethicon's Harmonic ACE®+7 device because the suit involves the same patents that were the subject of this ruling. Ethicon Endo-Surgery, Inc., et al. v. Covidien, Inc., et al. is a patent infringement action filed on December 14, 2011 in the United States District Court for the Southern District of Ohio, Western Division. The complaint alleges that the Company's Sonicision™ product infringes several of Ethicon's design and utility patents. Ethicon is seeking monetary damages and injunctive relief. The parties have engaged in discovery and pre-trial motion practice. The Company believes that it has meritorious defenses to these claims and is vigorously defending against them. On January 22, 2014, the district court entered summary judgment in the Company's favor, ruling that the Company does not infringe any of the seven Ethicon patents in dispute and declaring five of Ethicon's patents invalid. Ethicon has appealed the district court's decision.

Other Matters—One of the Company's subsidiaries, ev3 Inc., acquired Appriva Medical, Inc. in 2002. The acquisition agreement relating to ev3's acquisition of Appriva Medical contained four contingent milestone payments totaling \$175 million. ev3 determined that the milestones were not achieved by the applicable dates and that none of the milestones were payable. On April 7, 2009, Michael Lesh and Erik Van Der Burg, acting jointly as the Shareholder Representatives for the former shareholders of Appriva Medical, filed a motion to amend their previously dismissed complaints in Superior Court of the State of Delaware. The amended complaint sought recovery of all of the \$175 million milestone payments, as well as punitive damages. The plaintiffs asserted several claims, including breach of contract, fraudulent inducement and violation of California securities law.

On May 1, 2013, the jury returned a verdict finding that ev3 breached the merger agreement and awarded \$175 million in damages plus interest to the plaintiffs. Since the jury did not find fraud, the jury did not have the option of awarding punitive damages. The Company estimates that its possible range of loss is \$0 to \$295 million, which includes approximately \$120 million of potential post judgment interest, assuming a trial takes place within the next year. On August 29, 2013, the court denied the Company's motions for judgment as a matter of law and for a new trial. The Company appealed the verdict to the Delaware Supreme Court; oral argument for the appeal was held before a panel of judges on March 12, 2014. The Delaware Supreme Court subsequently ordered a rehearing before the full court, which was held on September 10, 2014. On September 30, 2014, the Delaware Supreme Court reversed the jury's verdict and remanded the case for a new trial. No liability has been recorded with respect to any damage award. The Company is a defendant in a number of other pending legal proceedings incidental to present and former operations, acquisitions and dispositions. The Company does not expect the outcome of these proceedings, either individually or in the aggregate, to have a material adverse effect on its results of operations, financial condition or cash flows.

Environmental Proceedings

The Company is involved in various stages of investigation and cleanup related to environmental remediation matters at a number of sites. These projects relate to a variety of activities, including removal of solvents, metals and other hazardous substances from soil and groundwater. The ultimate cost of site cleanup and timing of future cash flows is difficult to predict given uncertainties regarding the extent of the required cleanup, the interpretation of applicable laws and regulations, and alternative cleanup methods. As of December 26, 2014, the Company concluded that it was probable that it would incur investigation and remedial costs of \$179 million, of which \$24 million was included in accrued and other current liabilities and \$155 million was included in other liabilities on the condensed consolidated balance sheet. The most significant of these liabilities pertains to a site in Orrington, Maine, which is discussed below. The Company believes that any potential payment of such estimated amounts will not have a material adverse effect on its results of operations, financial condition or cash flows.

The Company is a successor to a company which owned and operated a chemical manufacturing facility in Orrington, Maine from 1967 until 1982. The Company is responsible for the costs of completing an environmental site investigation required by the United States Environmental Protection Agency (EPA) and the Maine Department of Environmental Protection (MDEP). Based on the site investigation, the Company submitted a Corrective Measures

Study plan and identified a preferred alternative which was submitted to the EPA and MDEP for approval in 2004. MDEP disagreed with the proposed alternative and served a compliance order on Mallinckrodt LLC and United States Surgical Corporation in December 2008. The compliance order included a directive to remove a significant volume of soils at the site. On December 19, 2008, the Company filed an appeal with the Maine Board of Environmental Protection (Maine Board) to challenge the terms of the compliance order. A hearing before the Maine Board began on January 25, 2010 and concluded on February 4, 2010. On August 19, 2010, the Maine Board modified the MDEP order and issued a final order requiring removal of two landfills, capping of the remaining three landfills, installation of a groundwater extraction system and long-term monitoring of the site and the three remaining landfills.

COVIDIEN PLC
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

On April 3, 2014, the Maine Supreme Judicial Court affirmed the Maine Board's compliance order. The Company has proceeded with implementation of the investigation and remediation in accordance with the MDEP order as modified by the Maine Board order.

The Company has also been involved in a lawsuit filed in the U.S. District Court for the District of Maine by the Natural Resources Defense Council and the Maine People's Alliance. Plaintiffs sought an injunction requiring the Company to conduct extensive studies of mercury contamination of the Penobscot River and Bay and options for remediating such contamination, and to perform appropriate remedial activities, if necessary.

On July 29, 2002, following a March 2002 trial, the District Court entered an opinion and order which held that conditions in the Penobscot River and Bay may pose an imminent and substantial endangerment and that the Company was liable for the cost of performing a study of the river and bay. The District Court subsequently appointed an independent study panel to oversee the study and ordered the Company to pay costs associated with the study. The study panel conducted a Phase I study and completed a Phase II study which included several years of field work and data collection. The study panel issued the Phase II Penobscot River Mercury Study Report (Phase II Report) on April 17, 2013. The Phase II Report contains recommendations for a variety of potential remedial options which could be implemented individually or in a variety of combinations. The Phase II Report also includes preliminary cost estimates for the potential remedial options. These cost estimates, which the report describes as "very rough estimates of cost," range from \$25 million to \$235 million, depending upon which potential option or combination of potential options are implemented, if any. The Phase II Report indicates that these costs are subject to uncertainties, and that before any remedial option is implemented, further engineering studies and engineering design work are necessary to determine the feasibility of the proposed remedial options. The Company has reviewed the Phase II Report with its outside legal and technical consultants and believes there are significant problems with the conclusions and recommendations in the report. The Company does not believe extensive remediation is necessary and intends to vigorously defend its position. In addition, no remediation order has been issued by any regulatory authority or the District Court. However, the Company has developed a proposal for certain limited studies and a proposal for monitoring some wildlife species, including but not limited to, certain fish and birds. The estimated costs of the proposed studies and monitoring have been accrued, the amounts of which are not significant. The trial was completed on June 27, 2014 and post-trial briefing was completed on September 30, 2014. This matter remains pending with the District Court.

Income Taxes

The income tax returns of the Company and its subsidiaries are periodically examined by various tax authorities. The U.S. Internal Revenue Service (IRS) continues to audit the Company's U.S. federal income tax returns for the years 2008 through 2009 and 2010 through 2012. Fieldwork for the 2008 through 2009 audit is expected to conclude in fiscal 2015. Open periods for examination also include certain periods during which the Company was a subsidiary of Tyco International. The resolution of these matters is subject to the conditions set forth in the Tyco tax sharing agreement. Tyco International has the right to administer, control and settle all U.S. income tax audits for periods prior to the 2007 separation. The Company has potential liabilities related to these income tax returns and has included its best estimate of potential liabilities for these years within current and non-current income taxes payable on its condensed consolidated balance sheets. With respect to these potential income tax liabilities, Covidien believes that the amounts recorded on its condensed consolidated balance sheets are adequate.

The IRS has concluded its field examination of certain of Tyco International's U.S. federal income tax returns for the years 1997 through 2000 and proposed tax adjustments, several of which also affect Covidien's income tax returns for certain years after 2000. Tyco International has appealed certain of the tax adjustments proposed by the IRS and has resolved all but one of the matters associated with the proposed tax adjustments. With respect to the outstanding issue that remains in dispute, on June 20, 2013, Tyco International advised the Company that it had received Notices of Deficiency from the IRS asserting that several of Tyco International's former U.S. subsidiaries owe additional taxes of \$914 million plus penalties of \$154 million based on audits of the 1997 through 2000 tax years of Tyco International

and its subsidiaries as they existed at that time. These amounts exclude interest and do not reflect the impact on subsequent periods if the IRS position is ultimately proved correct. The IRS has asserted in the Notices of Deficiency that substantially all of Tyco International's intercompany debt originating during the years 1997 through 2000 should not be treated as debt for U.S. federal income tax purposes, and has disallowed interest deductions related to the intercompany debt and certain tax attribute adjustments recognized on Tyco International's U.S. income tax returns totaling approximately \$3.0 billion. The Company strongly disagrees with the IRS's proposed adjustments. On July 22, 2013, Tyco International filed a petition with the U.S. Tax Court contesting the IRS assessment. The Company believes there are meritorious defenses for the tax filings in question, that the IRS positions with regard to these matters are inconsistent with the applicable tax laws and existing Treasury regulations, and that the previously reported taxes for the years in question are appropriate.

COVIDIEN PLC
 NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
 (Unaudited)

No payments with respect to these matters or any additional matters that may be raised by the U.S. Tax Court would be required until the dispute is definitively resolved, which could take several years. While Covidien believes that the amounts recorded as non-current income taxes payable and guaranteed contingent tax liabilities related to these matters are adequate, the timing and outcome of such litigation is highly uncertain and could have a material adverse effect on the condensed consolidated financial statements. In particular, if the IRS is successful in asserting its claim, it would likely assert that approximately \$6.6 billion of interest deductions with respect to Tyco International's intercompany debt in subsequent time periods should also be disallowed.

Tyco International's income tax returns for the years 2001 through 2003 remain subject to adjustment by the IRS upon ultimate resolution of the disputed issue involving certain intercompany loans that originated during 1997 through 2000. During the first quarter of fiscal 2015, the Company reached an effective settlement with the IRS on all tax matters within the 2004 tax year that remained outstanding following the effective settlement of certain matters during fiscal 2014.

15. Redeemable Noncontrolling Interest

In January 2014, the Company acquired 65% of the outstanding shares of Changzhou Kangdi Medical Stapler Co., Ltd. (Kangdi). Covidien has the option to purchase the remaining shares of Kangdi, and the noncontrolling shareholders have the option to sell their shares to Covidien, in fiscal 2019, or earlier if certain revenue targets are achieved. The price Covidien would have to pay to purchase the remaining shares is between \$60 million and \$96 million, the final determination of which will be based on the achievement of certain revenue targets. Since the noncontrolling interest shareholders can require Covidien to purchase their shares, their 35% equity interest has been classified as a redeemable noncontrolling interest.

Redeemable noncontrolling interest is considered to be temporary equity and is therefore reported between liabilities and equity on the condensed consolidated balance sheet. Since the noncontrolling interest becomes redeemable in fiscal 2019, or earlier under certain circumstances, the Company records the redeemable noncontrolling interest at the greater of: (a) the initial carrying amount increased or decreased for the noncontrolling interest's share of Kangdi's net income or loss; or (b) its estimated redemption value at the end of each reporting period. The Company records changes in the estimated redemption value of the noncontrolling interest through net income. For the quarter ended December 26, 2014, net loss attributable to the redeemable noncontrolling interest and the adjustments to the estimated redemption value were included in other income, net in the condensed consolidated statement of income, as the amount was insignificant. As of December 26, 2014, the estimated redemption value of the noncontrolling interest approximated the carrying value.

16. Accumulated Other Comprehensive Income

The components of accumulated other comprehensive income for the quarter ended December 26, 2014 were as follows:

| (Dollars in Millions) | Currency Translation | Unrecognized (Loss) Gain on Benefit Plans | Unrecognized Loss on Derivatives | Unrecognized Gain on Investment | Accumulated Other Comprehensive Income (Loss) |
|--|----------------------|---|----------------------------------|---------------------------------|---|
| Balance at September 26, 2014 | \$301 | \$(124) | \$(32) | \$— | \$145 |
| Change before reclassifications to earnings ⁽¹⁾ | (120) | 6 | (7) ⁽²⁾ | 5 | (116) |
| Amounts reclassified to earnings ⁽¹⁾ | — | 2 ⁽³⁾ | — | — | 2 |
| Other comprehensive (loss) income | (120) | 8 | (7) | 5 | (114) |
| Balance at December 26, 2014 | \$181 | \$(116) | \$(39) | \$5 | \$31 |

⁽¹⁾ Presented net of income taxes, the amounts of which are insignificant.

⁽²⁾ Relates to commodity hedges.

- (3) Includes amortization of net actuarial losses included in net periodic benefit cost, the components of which are presented in note 5.

COVIDIEN PLC
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

17. Covidien International Finance S.A.

CIFSA, a Luxembourg company, is a holding company that is indirectly 100% owned by Covidien plc and owns, directly or indirectly, substantially all of the operating subsidiaries of Covidien plc. CIFSA is the issuer of the Company's senior notes and commercial paper, both of which are fully, unconditionally and joint and severally guaranteed by Covidien plc and Covidien Ltd., the owners of CIFSA. In addition, CIFSA is the borrower under the revolving credit facility, which is fully and unconditionally guaranteed by Covidien plc. The following information provides the composition of the Company's comprehensive income, assets, liabilities, redeemable noncontrolling interest, equity and cash flows by relevant group within the Company: Covidien plc and Covidien Ltd. as the guarantors, CIFSA as issuer of the debt, and the operating companies that represent assets of CIFSA. Condensed consolidating financial information for Covidien plc, Covidien Ltd. and CIFSA, on a stand alone basis, is presented using the equity method of accounting for subsidiaries.

CONDENSED CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME

Quarter Ended December 26, 2014

(dollars in millions)

| | Covidien plc | Covidien Ltd. | CIFSA | Other Subsidiaries | Consolidating Adjustments | Total | |
|--|--------------|---------------|--------|-----------------------|------------------------------|---------|---|
| Net sales | \$— | \$— | \$— | \$2,686 | \$— | \$2,686 | |
| Cost of goods sold | — | — | — | 1,042 | — | 1,042 | |
| Gross profit | — | — | — | 1,644 | — | 1,644 | |
| Selling, general and administrative expenses | 27 | — | 1 | 837 | — | 865 | |
| Research and development expenses | — | — | — | 133 | — | 133 | |
| Restructuring credits, net | — | — | — | (2 |) — | (2 |) |
| Operating (loss) income | (27 |) — | (1 |) 676 | — | 648 | |
| Interest expense | — | — | (48 |) — | — | (48 |) |
| Interest income | — | — | — | 3 | — | 3 | |
| Other expense, net | — | — | — | (20 |) — | (20 |) |
| Equity in net income of subsidiaries | 459 | 459 | 359 | — | (1,277 |) — | |
| Intercompany interest and fees | 77 | — | 149 | (226 |) — | — | |
| Income before income taxes | 509 | 459 | 459 | 433 | (1,277 |) 583 | |
| Income tax (benefit) expense | (2 |) — | — | 74 | — | 72 | |
| Net income | 511 | 459 | 459 | 359 | (1,277 |) 511 | |
| Other comprehensive loss, net of income taxes | (114 |) (114 |) (114 |) (115 |) 343 | (114 |) |
| Total comprehensive income | \$397 | \$ 345 | \$345 | \$244 | \$ (934 |) \$397 | |

COVIDIEN PLC
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

CONDENSED CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME

Quarter Ended December 27, 2013

(dollars in millions)

| | Covidien plc | Covidien Ltd. | CIFSA | Other Subsidiaries | Consolidating Adjustments | Total | |
|--|--------------|---------------|--------|-----------------------|------------------------------|----------|---|
| Net sales | \$— | \$— | \$— | \$2,639 | \$— | \$2,639 | |
| Cost of goods sold | — | — | — | 1,076 | — | 1,076 | |
| Gross profit | — | — | — | 1,563 | — | 1,563 | |
| Selling, general and administrative expenses | 28 | — | 1 | 821 | — | 850 | |
| Research and development expenses | — | — | — | 125 | — | 125 | |
| Restructuring charges, net | — | — | — | 57 | — | 57 | |
| Operating (loss) income | (28 |) — | (1 |) 560 | — | 531 | |
| Interest expense | — | — | (54 |) 1 | — | (53 |) |
| Interest income | — | — | — | 2 | — | 2 | |
| Other income | — | — | — | 33 | — | 33 | |
| Equity in net income of subsidiaries | 354 | 354 | 256 | — | (964 |) — | |
| Intercompany interest and fees | 71 | — | 153 | (224 |) — | — | |
| Income before income taxes | 397 | 354 | 354 | 372 | (964 |) 513 | |
| Income tax (benefit) expense | (1 |) — | — | 116 | — | 115 | |
| Net income | 398 | 354 | 354 | 256 | (964 |) 398 | |
| Other comprehensive loss, net of income taxes | (12 |) (12 |) (12 |) (13 |) 37 | (12 |) |
| Total comprehensive income | \$ 386 | \$ 342 | \$ 342 | \$ 243 | \$ (927 |) \$ 386 | |

COVIDIEN PLC
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

CONDENSED CONSOLIDATING BALANCE SHEET

At December 26, 2014

(dollars in millions)

| | Covidien plc | Covidien Ltd. | CIFSA | Other Subsidiaries | Consolidating Adjustments | Total |
|---|--------------|---------------|----------|-----------------------|------------------------------|----------|
| Assets | | | | | | |
| Current Assets: | | | | | | |
| Cash and cash equivalents | \$ — | \$ — | \$467 | \$1,351 | \$ — | \$1,818 |
| Accounts receivable trade, net | — | — | — | 1,451 | — | 1,451 |
| Inventories | — | — | — | 1,422 | — | 1,422 |
| Intercompany receivable | 19 | 60 | 7 | 23 | (109) | — |
| Prepaid expenses and other current assets | 6 | — | 1 | 889 | — | 896 |
| Total current assets | 25 | 60 | 475 | 5,136 | (109) | 5,587 |
| Property, plant and equipment, net | 1 | — | — | 1,983 | — | 1,984 |
| Goodwill | — | — | — | 8,823 | — | 8,823 |
| Intangible assets, net | — | — | — | 3,209 | — | 3,209 |
| Due from former parent and affiliate | — | — | — | 272 | — | 272 |
| Investment in subsidiaries | 9,171 | 9,019 | 14,561 | — | (32,751) | — |
| Intercompany loans receivable | 1,397 | 94 | 7,343 | 6,951 | (15,785) | — |
| Other assets | — | — | 51 | 689 | — | 740 |
| Total Assets | \$ 10,594 | \$ 9,173 | \$22,430 | \$27,063 | \$(48,645) | \$20,615 |
| Liabilities, Redeemable Noncontrolling Interest and Shareholders' Equity | | | | | | |
| Current Liabilities: | | | | | | |
| Current maturities of long-term debt | \$ — | \$ — | \$1,004 | \$6 | \$ — | \$1,010 |
| Accounts payable | 29 | — | — | 444 | — | 473 |
| Intercompany payable | 23 | — | — | 86 | (109) | — |
| Accrued and other current liabilities | 169 | — | 30 | 1,233 | — | 1,432 |
| Total current liabilities | 221 | — | 1,034 | 1,769 | (109) | 2,915 |
| Long-term debt | — | — | 4,029 | 22 | — | 4,051 |
| Income taxes payable | — | — | — | 974 | — | 974 |
| Guaranteed contingent tax liabilities | — | — | — | 555 | — | 555 |
| Intercompany loans payable | — | 2 | 8,348 | 7,435 | (15,785) | — |
| Other liabilities | 1 | — | — | 1,685 | — | 1,686 |
| Total Liabilities | 222 | 2 | 13,411 | 12,440 | (15,894) | 10,181 |
| Redeemable noncontrolling interest | — | — | — | 62 | — | 62 |
| Shareholders' Equity | 10,372 | 9,171 | 9,019 | 14,561 | (32,751) | 10,372 |
| Total Liabilities, Redeemable Noncontrolling Interest and Shareholders' Equity | \$ 10,594 | \$ 9,173 | \$22,430 | \$27,063 | \$(48,645) | \$20,615 |

COVIDIEN PLC
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

CONDENSED CONSOLIDATING BALANCE SHEET

At September 26, 2014

(dollars in millions)

| | Covidien plc | Covidien Ltd. CIFSA | Other Subsidiaries | Consolidating Adjustments | Total | |
|---|------------------|---------------------|--------------------|---------------------------|-------------------|------------------|
| Assets | | | | | | |
| Current Assets: | | | | | | |
| Cash and cash equivalents | \$ — | \$ — | \$ 375 | \$ 1,192 | \$ — | \$ 1,567 |
| Accounts receivable trade, net | — | — | — | 1,532 | — | 1,532 |
| Inventories | — | — | — | 1,408 | — | 1,408 |
| Intercompany receivable | 19 | 61 | — | 36 | (116) | — |
| Prepaid expenses and other current assets | 4 | — | 9 | 934 | — | 947 |
| Total current assets | 23 | 61 | 384 | 5,102 | (116) | 5,454 |
| Property, plant and equipment, net | 1 | — | — | 2,023 | — | 2,024 |
| Goodwill | — | — | — | 8,851 | — | 8,851 |
| Intangible assets, net | — | — | — | 3,282 | — | 3,282 |
| Due from former parent and affiliate | — | — | — | 280 | — | 280 |
| Investment in subsidiaries | 8,791 | 8,638 | 14,281 | — | (31,710) | — |
| Intercompany loans receivable | 1,452 | 94 | 7,343 | 6,852 | (15,741) | — |
| Other assets | — | — | 34 | 776 | — | 810 |
| Total Assets | \$ 10,267 | \$ 8,793 | \$ 22,042 | \$ 27,166 | \$(47,567) | \$ 20,701 |
| Liabilities, Redeemable Noncontrolling Interest and Shareholders' Equity | | | | | | |
| Current Liabilities: | | | | | | |
| Current maturities of long-term debt | \$ — | \$ — | \$ 1,004 | \$ 5 | \$ — | \$ 1,009 |
| Accounts payable | 2 | — | — | 499 | — | 501 |
| Intercompany payable | 36 | — | — | 80 | (116) | — |
| Accrued and other current liabilities | 169 | — | 84 | 1,525 | — | 1,778 |
| Total current liabilities | 207 | — | 1,088 | 2,109 | (116) | 3,288 |
| Long-term debt | — | — | 4,012 | 23 | — | 4,035 |
| Income taxes payable | — | — | — | 987 | — | 987 |
| Guaranteed contingent tax liabilities | — | — | — | 555 | — | 555 |
| Intercompany loans payable | — | 2 | 8,304 | 7,435 | (15,741) | — |
| Other liabilities | — | — | — | 1,716 | — | 1,716 |
| Total Liabilities | 207 | 2 | 13,404 | 12,825 | (15,857) | 10,581 |
| Redeemable noncontrolling interest | — | — | — | 60 | — | 60 |
| Shareholders' Equity | 10,060 | 8,791 | 8,638 | 14,281 | (31,710) | 10,060 |
| Total Liabilities, Redeemable Noncontrolling Interest and Shareholders' Equity | \$ 10,267 | \$ 8,793 | \$ 22,042 | \$ 27,166 | \$(47,567) | \$ 20,701 |

COVIDIEN PLC
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

CONDENSED CONSOLIDATING STATEMENT OF CASH FLOWS

Quarter Ended December 26, 2014

(dollars in millions)

| | Covidien plc | Covidien Ltd. | CIFSA | Other Subsidiaries | Consolidating Adjustments | Total |
|---|--------------|---------------|--------|-----------------------|------------------------------|----------|
| Cash Flows From Operating Activities: | | | | | | |
| Net cash (used in) provided by operating activities | \$ (39) | \$ — | \$ 49 | \$ 441 | \$ — | \$ 451 |
| Cash Flows From Investing Activities: | | | | | | |
| Capital expenditures | — | — | — | (60) | — | (60) |
| Net decrease in intercompany loans | — | — | 43 | — | (43) | — |
| Other | — | — | — | (2) | — | (2) |
| Net cash provided by (used in) investing activities | — | — | 43 | (62) | (43) | (62) |
| Cash Flows From Financing Activities: | | | | | | |
| Dividends paid | (163) | — | — | — | — | (163) |
| Repurchase of shares | (25) | — | — | — | — | (25) |
| Proceeds from exercise of share options | 44 | — | — | — | — | 44 |
| Net intercompany loan borrowings (repayments) | 55 | — | — | (98) | 43 | — |
| Other | 128 | — | — | (93) | — | 35 |
| Net cash provided by (used in) financing activities | 39 | — | — | (191) | 43 | (109) |
| Effect of currency rate changes on cash | — | — | — | (29) | — | (29) |
| Net increase in cash and cash equivalents | — | — | 92 | 159 | — | 251 |
| Cash and cash equivalents at beginning of period | — | — | 375 | 1,192 | — | 1,567 |
| Cash and cash equivalents at end of period | \$ — | \$ — | \$ 467 | \$ 1,351 | \$ — | \$ 1,818 |

COVIDIEN PLC
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

CONDENSED CONSOLIDATING STATEMENT OF CASH FLOWS
Quarter Ended December 27, 2013
(dollars in millions)

| | Covidien plc | Covidien Ltd. | CIFSA | Other Subsidiaries | Consolidating Adjustments | Total |
|---|--------------|---------------|--------|-----------------------|------------------------------|----------|
| Cash Flows From Operating Activities: | | | | | | |
| Net cash (used in) provided by operating activities | \$ (11) | \$ (1) | \$ 44 | \$ 189 | \$ — | \$ 221 |
| Cash Flows From Investing Activities: | | | | | | |
| Capital expenditures | — | — | — | (61) | — | (61) |
| Acquisition, net of cash acquired | — | — | — | (24) | — | (24) |
| Net increase in intercompany loans | — | — | (182) | — | 182 | — |
| Other | — | — | (1) | (4) | 1 | (4) |
| Net cash used in investing activities | — | — | (183) | (89) | 183 | (89) |
| Cash Flows From Financing Activities: | | | | | | |
| Dividends paid | (145) | — | — | — | — | (145) |
| Repurchase of shares | (312) | — | — | — | — | (312) |
| Proceeds from exercise of share options | 44 | — | — | — | — | 44 |
| Net intercompany loan borrowings (repayments) | 331 | 1 | — | (150) | (182) | — |
| Other | 93 | — | — | (88) | (1) | 4 |
| Net cash provided by (used in) financing activities | 11 | 1 | — | (238) | (183) | (409) |
| Effect of currency rate changes on cash | — | — | — | (10) | — | (10) |
| Net decrease in cash and cash equivalents | — | — | (139) | (148) | — | (287) |
| Cash and cash equivalents at beginning of period | — | — | 479 | 1,389 | — | 1,868 |
| Cash and cash equivalents at end of period | \$ — | \$ — | \$ 340 | \$ 1,241 | \$ — | \$ 1,581 |

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our condensed consolidated financial statements and the accompanying notes included in this Quarterly Report. The following discussion may contain forward-looking statements that reflect our plans, estimates and beliefs and involve risks, uncertainties and assumptions. Our actual results could differ materially from those discussed in these forward-looking statements. Factors that could cause or contribute to these differences include those discussed under the headings "Risk Factors" and "Forward-Looking Statements" in both our Annual Report on Form 10-K for the fiscal year ended September 26, 2014 and in this Quarterly Report.

Overview

We develop, manufacture and sell healthcare products for use in clinical and home settings. Our mission is to create and deliver innovative healthcare solutions, developed in ethical collaboration with medical professionals, which enhance the quality of life for patients and improve outcomes for our customers and our shareholders.

Our reportable segments are as follows:

Medical Devices includes worldwide sales of the following products: advanced and general surgical solutions, peripheral vascular and neurovascular therapies, patient monitoring products, and airway and ventilation products. It also includes sales of the following products outside the United States: nursing care, medical surgical, SharpSafety™ and original equipment manufacturer (OEM) products.

U.S. Medical Supplies includes sales of the following products in the United States: nursing care, medical surgical, SharpSafety™ and OEM products.

Recent Development

On January 6, 2015, shareholders of Covidien and Medtronic, Inc. approved the acquisition of Covidien by Medtronic in a cash-and-stock transaction. Under the agreement, each outstanding ordinary share of Covidien will be converted into the right to receive \$35.19 in cash and 0.956 of an ordinary share of Medtronic plc (a newly formed Irish company). Cash will be paid in lieu of any fractional share amounts. The consummation of the transaction is subject to approval by the Irish High Court. The Irish High Court has set January 26, 2015 to hear our petition to sanction the scheme of arrangement under which Medtronic will acquire Covidien. If the Irish High Court sanctions the scheme of arrangement at the January 26, 2015 hearing, the transaction is expected to close on or prior to January 29, 2015. In anticipation of the close of the transaction, on January 20, 2015, Covidien canceled all of the ordinary shares that were held as treasury shares.

Restructuring Initiatives

In fiscal 2013, we launched a restructuring program designed to improve our cost structure. This program includes actions across our segments and corporate. Such actions include, among other things, reducing corporate expenses, expanding the use of shared services in low-cost locations, outsourcing services where appropriate, streamlining our organizational structure, consolidating manufacturing locations, consolidating and optimizing distribution centers and expanding low-cost country sourcing. We expect to incur aggregate charges between \$350 million and \$450 million associated with these actions, of which approximately \$100 million is estimated to be non-cash charges associated with facility closures. The remaining amount is expected to relate primarily to severance and termination costs, which we plan to fund using cash generated from operations. These charges, which are recorded as the specific actions required to execute on these initiatives are identified and approved, are expected to be incurred through fiscal 2018. Management is targeting savings from this program of \$250 million to \$300 million on an annualized basis once the program is completed. As of December 26, 2014, we had incurred \$124 million of net restructuring and related charges under this program since its inception. This program excludes restructuring actions associated with acquisitions.

In fiscal 2011, we launched a \$275 million restructuring program designed to improve our cost structure. This program includes actions across our segments and corporate and excludes restructuring actions associated with acquisitions. Charges totaling approximately \$50 million recorded under this program by our former Pharmaceuticals business have been reclassified to discontinued operations. Accordingly, aggregate charges of approximately \$225 million are expected to relate to our continuing operations. These charges, which are recorded as the specific actions required to execute on these initiatives are identified and approved, are expected to be incurred by the end of 2015.

Savings from this program are estimated to be approximately \$190 million on an annualized basis. During the first quarter of fiscal 2014, we recorded net restructuring and related charges associated with all restructuring programs and acquisitions of \$59 million. Restructuring activity during the first quarter of fiscal 2015 was insignificant.

Additional information regarding restructuring and related charges is provided in “Results of Operations—Restructuring (credits) charges, net” and in note 4 to our condensed consolidated financial statements.

Exit of Renal Denervation Program

In connection with management’s regular review of strategic programs and growth potential for our product portfolio, management decided to exit our OneShot™ renal denervation program. This decision was primarily driven by slower than expected development of the renal denervation market. The following table summarizes the financial impact the decision to exit our renal denervation program had on our results of operations for the first quarter of fiscal 2014:

(Dollars in Millions)

| | | |
|---|------|---|
| Impairment of completed technology | \$28 | |
| Other pre-tax charges ⁽¹⁾ | 7 | |
| Reversal of contingent consideration | (26 |) |
| Total pre-tax charges | 9 | |
| Income tax benefit on pre-tax charges | (11 |) |
| Income tax expense on contingent consideration reversal | 2 | |
| Write-off of prepaid tax asset | 22 | |
| Net income tax expense | 13 | |
| Total charges, net of income tax expense | \$22 | |

⁽¹⁾ Other pre-tax charges primarily relate to the write-down of inventory and contract cancellation.

During the first quarter of fiscal 2014, we determined that the post-market clinical trial associated with the radiofrequency energy-based renal denervation device (RF Device) to treat hypertension would not be successfully completed within the required timeframe. Accordingly, we reversed the \$20 million contingent consideration liability associated with the achievement of this milestone. In addition, as a result of our decision to exit our renal denervation program, we reversed \$6 million of contingent consideration liabilities that were primarily associated with the achievement of revenue targets for the RF Device.

Results of Operations

Quarters Ended December 26, 2014 and December 27, 2013

Net sales

Net sales by reportable segment were as follows:

| (Dollars in Millions) | Quarter Ended | | Percent Change | Currency Impact | Operational Growth ⁽¹⁾ | |
|-----------------------|-------------------|-------------------|----------------|-----------------|-----------------------------------|---|
| | December 26, 2014 | December 27, 2013 | | | | |
| Medical Devices | \$2,278 | \$2,251 | 1 | % (5 |)% 6 | % |
| U.S. Medical Supplies | 408 | 388 | 5 | — | 5 | |
| Total Covidien | \$2,686 | \$2,639 | 2 | (4 |) 6 | |

Operational growth is a non-GAAP financial measure, which should be considered supplemental to, and not a ⁽¹⁾substitute for, our reported financial results prepared in accordance with U.S. GAAP. See “Management’s Use of Non-GAAP Measures.”

Net sales in the first quarter of fiscal 2015 increased \$47 million, or 2%, to \$2.686 billion, compared with \$2.639 billion in the first quarter of fiscal 2014. The increase in net sales was driven by increased sales volume and a more favorable product mix, as well as the impact of prior year acquisitions, particularly the acquisition of Given Imaging. These increases in net sales were partially offset by the impact of unfavorable currency exchange fluctuations of \$114 million. The primary currency exchange rate movements that negatively impacted our consolidated net sales growth during the first quarter of fiscal 2015 were the U.S. dollar compared to the euro and the Japanese yen.

The increase in net sales of our Medical Devices segment was driven by the impact of the Given Imaging acquisition, which was acquired during the second quarter of fiscal 2014, and sales growth of stapling and vessel sealing products. The increase in net sales of our U.S. Medical Supplies segment primarily resulted from increases in sales of SharpSafety™, medical surgical and enteral feeding products. These increases were partially offset by a decline in sales of incontinence products.

Net sales by major product line were as follows:

| (Dollars in Millions) | Quarter Ended | | Percent Change | Currency Impact | Operational Growth ⁽¹⁾ |
|------------------------------|-------------------|-------------------|----------------|-----------------|-----------------------------------|
| | December 26, 2014 | December 27, 2013 | | | |
| Advanced Surgical | \$928 | \$853 | 9 | % (5)% | 14 |
| General Surgical | 385 | 408 | (6 |) (5) | (1) |
| Surgical Solutions | 1,313 | 1,261 | 4 | (5) | 9 |
| Peripheral Vascular | 308 | 315 | (2 |) (3) | 1 |
| Neurovascular | 120 | 110 | 9 | (4) | 13 |
| Vascular Therapies | 428 | 425 | 1 | (3) | 4 |
| Patient Monitoring | 251 | 250 | — | (4) | 4 |
| Airway & Ventilation | 166 | 182 | (9 |) (6) | (3) |
| Nursing Care | 257 | 259 | (1 |) (3) | 2 |
| Patient Care | 271 | 262 | 3 | (3) | 6 |
| Respiratory and Patient Care | 945 | 953 | (1 |) (3) | 2 |
| Total Covidien | \$2,686 | \$2,639 | 2 | (4) | 6 |

Operational growth is a non-GAAP financial measure, which should be considered supplemental to, and not a ⁽¹⁾substitute for, our reported financial results prepared in accordance with U.S. GAAP. See “Management’s Use of Non-GAAP Measures.”

Surgical Solutions—Surgical Solutions consists of the following:

• **Advanced Surgical**, which primarily includes sales of stapling, vessel sealing, fixation (hernia mechanical devices), mesh, hardware and ablation products, and interventional lung and gastrointestinal solutions.

• **General Surgical**, which primarily includes sales of surgical instruments, sutures and electro-surgery products.

Surgical Solutions net sales increased \$52 million, or 4%, to \$1.313 billion in the first quarter of fiscal 2015, compared with \$1.261 billion in the first quarter of fiscal 2014. Unfavorable currency exchange decreased net sales by \$68 million. Excluding the impact of currency exchange, Surgical Solutions sales growth primarily resulted from the acquisition of Given Imaging in February 2014, which contributed \$48 million of net sales in the first quarter of fiscal 2015. The remaining net increase in sales was primarily attributable to sales growth of stapling products, namely our Tri-Staple™ reloads outside the United States, and vessel sealing products, largely driven by prior year product launches, including LigaSure Impact™ and LigaSure™ Blunt Tip.

Within General Surgical, the decrease in sales primarily resulted from the divestiture of our biosurgery sealant product line in January 2014 and, to a lesser extent, lower sales of surgical instruments. These decreases were partially offset by the impact of the New Wave acquisition and increased sales of electro-surgery products.

Vascular Therapies—Vascular Therapies consists of the following:

• **Peripheral Vascular**, which includes sales of compression, dialysis, venous insufficiency products, peripheral stents and directional artherectomy products, as well as other products to support procedures.

• **Neurovascular**, which includes sales of coils, neurovascular stents and flow diversion products, as well as access and delivery products to support procedures.

Vascular Therapies net sales in the first quarter of fiscal 2015 were level with the comparable prior year period.

Unfavorable currency exchange fluctuations decreased net sales by \$15 million. Excluding the impact of currency

exchange, the increase in net sales was primarily driven by sales growth in Neurovascular products across all product lines, namely access and delivery and flow diversion products. Peripheral Vascular products sales were even with the prior year, as increased sales of chronic venous insufficiency products were offset by decreased sales of compression products.

Respiratory and Patient Care—Respiratory and Patient Care consists of the following:

• Patient Monitoring, which includes sales of sensors, monitors and temperature management products.

• Airway & Ventilation, which primarily includes sales of airway, ventilator and inhalation therapy products, and breathing systems.

• Nursing Care, which primarily includes sales of incontinence, enteral feeding, wound care, urology and suction products.

• Patient Care, which includes sales of medical surgical products, such as operating room supply products and electrodes; OEM products, which are various medical supplies manufactured for other medical products companies; and SharpSafety™ products, which includes needles, syringes and sharps disposal products.

Respiratory and Patient Care net sales decreased \$8 million to \$945 million in the first quarter of fiscal 2015, compared with \$953 million in the first quarter of fiscal 2014. Unfavorable currency exchange fluctuations decreased net sales by \$31 million. Excluding the impact of currency exchange, the increase in sales was attributable to sales growth in Patient Care and Patient Monitoring, partially offset by decreased sales of Airway & Ventilation. Sales growth in Patient Care was primarily attributable to increased sales of medical surgical and SharpSafety™ products, while Patient Monitoring sales growth mainly resulted from increased sales of capnography products and pulse oximetry sensors. The decline in sales of Airway & Ventilation was largely due to decreased sales of acute care ventilators and airway products.

Net sales by geographic area, based primarily on the location of the customer, were as follows:

| (Dollars in Millions) | Quarter Ended | | Percent Change | Currency Impact | Operational Growth ⁽¹⁾ |
|---|-------------------|-------------------|----------------|-----------------|-----------------------------------|
| | December 26, 2014 | December 27, 2013 | | | |
| United States | \$533 | \$479 | 11 | % — | % 11 |
| Non-U.S. Developed Markets ⁽²⁾ | 527 | 539 | (2) |) (9 |) 7 |
| Emerging Markets ⁽³⁾ | 253 | 243 | 4 | (8 |) 12 |
| Surgical Solutions | 1,313 | 1,261 | 4 | (5 |) 9 |
| United States | 246 | 237 | 4 | — | 4 |
| Non-U.S. Developed Markets ⁽²⁾ | 122 | 130 | (6) |) (9 |) 3 |
| Emerging Markets ⁽³⁾ | 60 | 58 | 3 | (5 |) 8 |
| Vascular Therapies | 428 | 425 | 1 | (3 |) 4 |
| United States | 612 | 591 | 4 | — | 4 |
| Non-U.S. Developed Markets ⁽²⁾ | 242 | 265 | (9) |) (9 |) — |
| Emerging Markets ⁽³⁾ | 91 | 97 | (6) |) (8 |) 2 |
| Respiratory and Patient Care | 945 | 953 | (1) |) (3 |) 2 |
| United States | 1,391 | 1,307 | 6 | — | 6 |
| Non-U.S. Developed Markets ⁽²⁾ | 891 | 934 | (5) |) (9 |) 4 |
| Emerging Markets ⁽³⁾ | 404 | 398 | 2 | (7 |) 9 |
| Total Covidien | \$2,686 | \$2,639 | 2 | (4 |) 6 |

Operational growth is a non-GAAP financial measure, which should be considered supplemental to, and not a

(1) substitute for, our reported financial results prepared in accordance with U.S. GAAP. See “Management’s Use of Non-GAAP Measures.”

(2) Non-U.S. Developed Markets includes Western Europe, Japan, Canada, Australia and New Zealand.

(3) Emerging Markets includes Eastern Europe, Middle East, Africa, Asia (excluding Japan) and Latin America.

United States—Net sales in the United States increased \$84 million, or 6%, during the first quarter of fiscal 2015, compared with the first quarter of fiscal 2014. This increase was primarily driven by Surgical Solutions and, to a lesser extent, Respiratory and Patient Care. The increase in sales within Surgical Solutions primarily resulted from the acquisition of Given Imaging in February 2014 and increased sales of stapling products, partially offset by the impact of the divestiture of our biosurgery sealant product line. Sales growth in Respiratory and Patient Care was mainly due to increased sales of

SharpSafety™, medical surgical products and enteral feeding products. Higher capnography products and ventilator sales also contributed to the sales growth for Respiratory and Patient Care. These increases in net sales for Respiratory and Patient Care were partially offset by a decrease in sales of incontinence and airway products.

Non-U.S. Developed Markets—Net sales in Non-U.S. Developed Markets decreased \$43 million, or 5%, during the first quarter of fiscal 2015, compared with the first quarter of fiscal 2014. Unfavorable currency exchange fluctuations decreased net sales by \$83 million. Excluding the impact of currency exchange, the increase in sales was primarily driven by Surgical Solutions, resulting largely from increased sales of stapling products, most notably in Western Europe. In addition, the acquisition of Given Imaging in February 2014 also contributed to the Surgical Solutions sales growth.

Emerging Markets—Net sales in Emerging Markets increased \$6 million, or 2%, during the first quarter of fiscal 2015, compared with the first quarter of fiscal 2014. Unfavorable currency exchange fluctuations decreased net sales by \$31 million. Excluding the impact of currency exchange, the increase in sales was primarily driven by Surgical Solutions, largely as a result of increased sales of stapling products in Asia. This increase was partially offset by a decline in sales of Respiratory and Patient Care, primarily as a result of decreased sales of ventilators in Asia and Latin America.

Operating Expenses

A summary of certain operating expenses were as follows:

| | Quarter Ended | | December 27, 2013 | | |
|--|-------------------|----------------|-------------------|----------------|---|
| | December 26, 2014 | | December 27, 2013 | | |
| (Dollars in Millions) | \$ Amount | % of Net Sales | \$ Amount | % of Net Sales | |
| Cost of goods sold | \$1,042 | 38.8 | % \$1,076 | 40.8 | % |
| Selling, general and administrative expenses | 865 | 32.2 | 850 | 32.2 | |
| Research and development expenses | 133 | 5.0 | 125 | 4.7 | |

Cost of goods sold—Cost of goods sold was 38.8% in the first quarter of fiscal 2015, compared with 40.8% of net sales in the first quarter of fiscal 2014. The decrease in cost of goods sold as a percent of net sales primarily resulted from manufacturing cost reductions, increased sales volume and a more favorable product mix, partially offset by pricing pressure.

Selling, general and administrative expenses—Selling, general and administrative expenses in the first quarter of fiscal 2015 increased \$15 million, or 1.8%, to \$865 million, compared with \$850 million in the first quarter of fiscal 2014. This increase was primarily driven by increased expenses resulting from acquisitions completed in the previous fiscal year and transaction costs incurred in connection with our pending acquisition by Medtronic, partially offset by the impact of cost savings initiatives. As a percentage of our net sales, selling, general and administrative expenses were 32.2% in the first quarter of both fiscal 2015 and fiscal 2014.

Research and development expenses—Research and development expenses increased \$8 million, or 6.4%, to \$133 million in the first quarter of fiscal 2015, compared with \$125 million in the first quarter of fiscal 2014. This increase was primarily due to spending resulting from our fiscal 2014 acquisitions, particularly Given Imaging. As a percentage of our net sales, research and development expenses were 5.0% in the first quarter of fiscal 2015, compared with 4.7% in the first quarter of fiscal 2014.

Restructuring (credits) charges, net—During the first quarter of fiscal 2015, we recorded a net restructuring credit of \$2 million, compared with net restructuring and related charges of \$59 million during the first quarter of fiscal 2014. No restructuring actions were initiated during the current quarter due to the anticipated acquisition of Covidien by Medtronic. The \$59 million included \$2 million of charges included in cost of goods sold related to accelerated depreciation. The remaining \$57 million primarily related to severance and employee benefit costs incurred under our 2013 program associated with reorganizing our European operations.

Segment Operating Income

Refer to note 3 to our condensed consolidated financial statements for a summary of financial results by segment. The following is a summary of significant factors impacting segment financial results.

Medical Devices—Operating income for the first quarter of fiscal 2015 increased \$36 million to \$686 million, compared with \$650 million in the first quarter of fiscal 2014. Operating margin was 30.1% for the first quarter of fiscal 2015, compared with 28.9% for the first quarter of fiscal 2014. The increases in operating income and margin were primarily

due to the gross profit resulting from increased sales discussed under “Net Sales,” decreased manufacturing costs and the impact of cost savings

33

initiatives. These increases to operating income were partially offset by pricing pressure and the impact of fiscal 2014 acquisitions.

U.S. Medical Supplies—Operating income for the first quarter of fiscal 2015 increased \$21 million to \$60 million, compared with \$39 million in the first quarter of fiscal 2014. Operating margin was 14.7% for the first quarter of fiscal 2015, compared with 10.1% for the first quarter of fiscal 2014. The increases in operating income and margin primarily resulted from the favorable sales performance for the segment discussed under “Net Sales” and decreased manufacturing costs, partially offset by pricing pressure.

Corporate—Corporate expenses decreased \$8 million to \$82 million in the first quarter of fiscal 2015, compared with \$90 million in the first quarter of fiscal 2014. This decrease primarily resulted from lower expenses associated with employee benefits and compensation programs.

Non-Operating Items

Interest Expense and Interest Income—Interest expense decreased \$5 million to \$48 million in the first quarter of fiscal 2015, compared with \$53 million in the first quarter of fiscal 2014. This decrease resulted from the impact of interest rate swaps entered into during the third quarter of fiscal 2014. These swaps were terminated subsequent to the end of the quarter, resulting in a \$48 million gain that will be amortized to interest expense over the remaining life of the related debt. Interest income was \$3 million and \$2 million for the first quarter of fiscal 2015 and 2014, respectively.

Other (Expense) Income, Net—During the first quarter of fiscal 2015, we recorded other expense, net of \$20 million, which includes a loss under the Tyco tax sharing agreement of \$11 million that primarily reflects 58% of the interest and other income taxes payable amounts released during the quarter that are subject to the tax sharing agreement with Tyco International plc and TE Connectivity Ltd. In addition, during the first quarter of fiscal 2015, we began including net gains and losses on foreign exchange transactions and related gains and losses on associated hedge transactions in other (expense) income, net. These amounts had previously been included in costs of goods sold, to the extent they related to inventory transactions, or in selling, general and administrative expenses. During the first quarter of fiscal 2015, the net foreign currency loss recorded in other (expense) income, net was \$7 million. The comparative prior period amounts, which are presented in note 10 to our condensed consolidated financial statements, have not been reclassified to other (expense) income, net as the amounts were insignificant. The remaining \$2 million of other expense represents a loss on investments.

During the first quarter of fiscal 2014, we recorded other income, net of \$33 million, consisting primarily of a \$32 million increase to our receivable from Tyco International and TE Connectivity. This amount included \$25 million of income for our portion of Tyco International’s settlement of contract claims under a 2002 tax agreement with CIT Group Inc., a former subsidiary of Tyco International. The remaining \$7 million reflects 58% of the interest and other income taxes payable amounts recorded that are subject to the Tyco tax sharing agreement.

Income Tax Expense—Income tax expense was \$72 million and \$115 million on income before income taxes of \$583 million and \$513 million for the first quarter of fiscal 2015 and 2014, respectively. This resulted in effective tax rates of 12.3% and 22.4% for the first quarter of fiscal 2015 and 2014, respectively. The decrease in our effective tax rate primarily resulted from the effective settlement of certain tax matters within the 2004 U.S. audit and the retroactive re-enactment of the U.S. research and development credit, both of which occurred during the current period. Tax charges recorded in the prior period in connection with the exit of our OneShot™ renal denervation program and the anticipated settlement of certain tax matters within the 2005 through 2009 audit cycles also contributed to the decrease in our effective tax rate.

Management’s Use of Non-GAAP Measures

Operational growth, a non-GAAP financial measure, measures the change in sales between periods using a constant currency, the exchange rate in effect during the applicable prior year period. We have provided this non-GAAP financial measure because we believe it provides meaningful information regarding our results on a consistent and comparable basis for the periods presented. Management uses this non-GAAP financial measure, in addition to financial measures in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP), to evaluate our operating results. It is also one of the performance metrics that determines management incentive compensation. This non-GAAP financial measure should be considered supplemental to, and not a substitute for, our reported financial results prepared in accordance with U.S. GAAP.

Free cash flow, a non-GAAP measure, represents the cash that we have available to pursue opportunities that we believe enhance shareholder value. Management uses this non-GAAP financial measure, in addition to U.S. GAAP financial measures, to evaluate our operating results. It is also one of the performance metrics that determines management incentive compensation.

This non-GAAP financial measure should be considered supplemental to, and not a substitute for, our reported financial results prepared in accordance with U.S. GAAP.

Liquidity and Capital Resources

Our ongoing ability to generate cash from operations and access to the capital markets affects our ability to fund our capital needs. We believe, however, that our cash balances and other sources of liquidity, primarily our committed credit facility, will be sufficient to allow us to continue to invest in growth opportunities and fund operations for the foreseeable future.

A summary of our cash flows from operating, investing and financing activities is provided in the following table:

| (Dollars in Millions) | Quarter Ended | |
|---|----------------------|----------------------|
| | December 26, 2014 | December 27, 2013 |
| Net cash provided by (used in): | | |
| Operating activities | \$451 | \$221 |
| Investing activities | (62) | (89) |
| Financing activities | (109) | (409) |
| Effect of currency exchange rate changes on cash and cash equivalents | (29) | (10) |
| Net increase (decrease) in cash and cash equivalents | \$251 | \$(287) |

Operating Activities

Net cash provided by operating activities of \$451 million for the first quarter of fiscal 2015 was primarily attributable to net income, as adjusted for depreciation and amortization, partially offset by a working capital outflow of \$239 million, primarily resulting from a decrease in accrued and other liabilities of \$287 million and an increase in inventories of \$56 million. The decrease in accrued and other liabilities was largely driven by the annual payout of cash bonuses for performance in the prior fiscal year, a decrease in the amount due to Mallinckrodt and the semi-annual payment of interest on our public debt. These cash outflows were partially offset by a \$64 million decrease in the amount due from Mallinckrodt. The decreases in the amounts due to/from Mallinckrodt resulted from the termination of certain transition services agreements that were in place following the separation of Mallinckrodt plc from Covidien in June 2013.

Net cash provided by operating activities of \$221 million for the first quarter of fiscal 2014 was primarily attributable to net income, as adjusted for depreciation and amortization, partially offset by a working capital outflow of \$399 million, primarily resulting from a decrease in accrued and other liabilities of \$238 million and an increase in accounts receivable of \$82 million. The decrease in accrued and other liabilities was largely driven by the annual payout of cash bonuses for performance in the prior fiscal year and the semi-annual payment of interest on our public debt. The increase in accounts receivable primarily resulted from increased sales volume.

Investing Activities

Net cash used in investing activities was \$62 million and \$89 million for the first quarter of fiscal 2015 and 2014, respectively. The decrease in cash used in investing activities resulted primarily from \$24 million of spending on an acquisition in the prior year quarter. For the full year fiscal 2015, we expect capital expenditures to be in the range of \$350 million to \$400 million, which we expect to fund using cash generated from operations.

Financing Activities

Net cash used in financing activities was \$109 million and \$409 million for the first quarter of fiscal 2015 and 2014, respectively.

Dividend Payments—Dividend payments were \$163 million and \$145 million during the first quarter of fiscal 2015 and 2014, respectively.

Share Repurchases—Due to restrictions in the Medtronic transaction agreement entered into in June 2014 and under the Irish Takeover Rules, we did not make any purchases under our \$3.0 billion share repurchase program during the first quarter of fiscal 2015. We repurchased approximately 4.5 million shares for \$298 million during the first quarter of fiscal 2014 under our share buyback program. We also repurchased shares from certain employees in order to satisfy employee tax withholding requirements in connection with the vesting of restricted shares and to settle certain option exercises. We spent \$25 million and

\$14 million to acquire shares in connection with these equity-based awards during the first quarter of fiscal 2015 and 2014, respectively.

Option Exercises—Proceeds from option exercises were \$44 million for both the first quarter of fiscal 2015 and 2014.

Free Cash Flow

We returned 42% and 207% of our operating cash flow to shareholders during the first quarter of fiscal 2015 and 2014, respectively, through a combination of both dividend payments and share repurchases. Free cash flow returned to shareholders was 48% and 286% for the first quarter of fiscal 2015 and 2014, respectively.

Free cash flow was \$391 million for the first quarter of fiscal 2015, compared with \$160 million for the first quarter of fiscal 2014. This increase in free cash flow primarily resulted from higher earnings, a decrease in accounts receivables stemming from increased cash collections, particularly in Europe, compared with an increase in accounts receivables in the prior year quarter and a decrease in income taxes paid, net of refunds of approximately \$40 million.

Free cash flow is a non-GAAP financial measure, which should be considered supplemental to, and not a substitute for, our reported financial results prepared in accordance with U.S. GAAP. See “Management’s Use of Non-GAAP Measures.” Reconciliations between net cash provided by operating activities (the most comparable U.S. GAAP measure) and free cash flow are as follows:

| (Dollars in Millions) | Quarter Ended | |
|---|----------------------|----------------------|
| | December 26, 2014 | December 27, 2013 |
| Net cash provided by operating activities | \$451 | \$221 |
| Capital expenditures | (60 |) (61 |
| Free cash flow | \$391 | \$160 |

Capitalization

Shareholders’ equity was \$10.372 billion at December 26, 2014, compared with \$10.060 billion at September 26, 2014. The increase in shareholders’ equity was primarily due to net income of \$511 million, partially offset by dividends declared of \$163 million.

The following table contains several key measures to gauge our financial condition and liquidity at the end of each period:

| (Dollars in Millions) | December 26, 2014 | September 26, 2014 |
|--------------------------------------|----------------------|-----------------------|
| Cash and cash equivalents | \$1,818 | \$1,567 |
| Current maturities of long-term debt | 1,010 | 1,009 |
| Long-term debt | 4,051 | 4,035 |
| Total debt | 5,061 | 5,044 |
| Shareholders’ equity | 10,372 | 10,060 |
| Debt-to-total capital ratio | 33 | % 33 |

As of December 26, 2014, our cash and cash equivalents were held principally in subsidiaries which are located throughout the world. Under current laws, substantially all of these amounts can be repatriated to our Luxembourg subsidiary, Covidien International Finance S.A., which is the obligor of substantially all of our debt, and to our Irish parent company; however, the repatriation of these amounts could subject us to additional tax costs. We provide for tax liabilities in our financial statements with respect to amounts that we expect to repatriate; however, no tax liabilities are recorded for amounts that we consider to be permanently reinvested outside of Ireland. Our current plans do not demonstrate a need to repatriate earnings that are designated as permanently reinvested in order to fund our operations, including investing and financing activities.

We have a \$1.5 billion five-year unsecured senior revolving credit facility, which expires in 2019. In addition, we may increase this facility by up to \$500 million to a maximum of \$2.0 billion provided certain conditions are met. We are required to maintain an available unused balance under this credit facility sufficient to support amounts outstanding under our commercial paper program. At both December 26, 2014 and September 26, 2014, we had no commercial paper outstanding. In addition, no amount was outstanding under our credit facility at the end of either period.

Our credit facility agreement contains a covenant limiting our ratio of debt to earnings before interest, income taxes, depreciation and amortization. In addition, the agreement contains other customary covenants, none of which we consider restrictive to our operations. We are currently in compliance with all of our debt covenants.

Dividends

On December 19, 2014, our board of directors declared a quarterly cash dividend of \$0.36 per share, which is the maximum amount allowable under the Medtronic transaction agreement without prior written consent from Medtronic. The dividend, which totals \$163 million is payable during the second quarter of fiscal 2015 to shareholders of record at the close of business on January 2, 2015.

Commitments and Contingencies

Legal Proceedings

We are subject to various legal proceedings and claims, including patent infringement claims, products liability matters, environmental matters, employment disputes, contractual disputes and other commercial disputes. We believe that these legal proceedings and claims likely will be resolved over an extended period of time. Although it is not feasible to predict the outcome of these proceedings, based upon our experience, current information and applicable law, we do not expect that these proceedings will have a material adverse effect on our financial condition. However, one or more of the proceedings could have a material adverse effect on our results of operations or cash flows for a future period. Note 14 to our condensed consolidated financial statements and Part II, Item 1—Legal Proceedings provide additional information regarding legal proceedings.

Guarantees

In connection with our 2007 separation from Tyco International and TE Connectivity, we entered into guarantee commitments and indemnifications with Tyco International and TE Connectivity related to certain contingent tax liabilities. Current and non-current liabilities totaling \$577 million relating to these guarantees were included on our condensed consolidated balance sheet at December 26, 2014, a substantial portion of which is classified as non-current.

In connection with the 2013 separation, Mallinckrodt assumed the tax liabilities that are attributable to its subsidiaries, which amounted to approximately \$160 million. We have indemnified Mallinckrodt to the extent that such tax liabilities arising from periods prior to fiscal 2013 exceed \$200 million, net of certain tax benefits realized. In addition, in connection with the 2013 separation, we entered into certain other guarantee commitments and indemnifications with Mallinckrodt. The values attributable to the tax indemnification and other guarantees were insignificant.

In disposing of assets or businesses, we often provide representations, warranties and indemnities to cover various risks and liabilities, including unknown damage to the assets, environmental risks involved in the sale of real estate, liability to investigate and remediate environmental contamination at waste disposal sites and manufacturing facilities, and unidentified tax liabilities related to periods prior to disposition. We do not have the ability to estimate the potential liability from such indemnities because they relate to unknown conditions. However, we have no reason to believe that these uncertainties would have a material adverse effect on our results of operations, financial condition or cash flows.

We have recorded liabilities for known indemnification obligations included as part of environmental liabilities. In addition, we are liable for product performance; however, in the opinion of management, such obligations will not significantly affect our results of operations, financial condition or cash flows.

Off-Balance Sheet Arrangements

As of December 26, 2014, we had various outstanding letters of credit and guarantee and surety bonds totaling \$207 million, none of which were individually significant.

Income Taxes

At December 26, 2014, we are the primary obligor to the taxing authorities for \$1.007 billion of tax liabilities that are recorded on our condensed consolidated balance sheet, of which \$646 million relates to periods prior to our 2007 separation from Tyco International and is shared with Tyco International and TE Connectivity pursuant to the Tyco tax sharing agreement. However, the actual amounts that we may be required to ultimately accrue or pay under the Tyco tax sharing agreement could vary depending upon the outcome of the unresolved tax matters, some of which

may not be resolved for several years.

The Internal Revenue Service (IRS) has concluded its field examination of certain of Tyco International's U.S. federal income tax returns for the years 1997 through 2000 and proposed tax adjustments, several of which also affect our income tax returns for certain years after 2000. Tyco International has appealed certain of the tax adjustments proposed by the IRS and has

37

resolved all but one of the matters associated with the proposed tax adjustments. With respect to the outstanding issue that remains in dispute, on June 20, 2013, we were advised by Tyco International that it had received Notices of Deficiency from the IRS asserting that several of Tyco International's former U.S. subsidiaries owe additional taxes of \$914 million plus penalties of \$154 million based on audits of the 1997 through 2000 tax years of Tyco International and its subsidiaries as they existed at that time. These amounts exclude interest and do not reflect the impact on subsequent periods if the IRS position is ultimately proved correct. The IRS has asserted in the Notices of Deficiency that substantially all of Tyco International's intercompany debt originating during the years 1997 through 2000 should not be treated as debt for U.S. federal income tax purposes, and has disallowed interest deductions related to the intercompany debt and certain tax attribute adjustments recognized on Tyco International's U.S. income tax returns totaling approximately \$3.0 billion. We strongly disagree with the IRS's proposed adjustments. On July 22, 2013, Tyco International filed a petition with the U.S. Tax Court contesting the IRS assessment. We believe there are meritorious defenses for the tax filings in question, that the IRS positions with regard to these matters are inconsistent with the applicable tax laws and existing Treasury regulations, and that the previously reported taxes for the years in question are appropriate.

No payments with respect to these matters or any additional matters that may be raised by the U.S. Tax Court would be required until the dispute is definitively resolved, which could take several years. While we believe that the amounts recorded as non-current income taxes payable and guaranteed contingent tax liabilities related to these matters are adequate, the timing and outcome of such litigation is highly uncertain and could have a material adverse effect on our condensed consolidated financial statements. In particular, if the IRS is successful in asserting its claim, it would likely assert that approximately \$6.6 billion of interest deductions with respect to Tyco International's intercompany debt in subsequent time periods should also be disallowed.

Tyco International's income tax returns for the years 2001 through 2003 remain subject to adjustment by the IRS upon ultimate resolution of the disputed issue involving certain intercompany loans that originated during 1997 through 2000. During the first quarter of fiscal 2015, we reached an effective settlement with the IRS on all tax matters within the 2004 tax year that remained outstanding following the effective settlement of certain matters during fiscal 2014. Pursuant to the terms of the Tyco tax sharing agreement, we have current and non-current receivables from Tyco International and TE Connectivity totaling \$286 million at December 26, 2014. This amount primarily reflects 58% of our contingent tax liabilities that are subject to the Tyco tax sharing agreement. If Tyco International and TE Connectivity default on their obligations to us under the Tyco tax sharing agreement, however, we would be liable for the entire amount of such liabilities. Additional information regarding the Tyco tax sharing agreement is provided in note 12 to our condensed consolidated financial statements.

Concentration of Credit Risk

Financial instruments that potentially subject us to concentrations of credit risk primarily consist of cash and cash equivalents, derivative financial instruments and accounts receivable. We invest our excess cash in deposits or money market funds and diversify the concentration of cash among different financial institutions that have at least an A-credit rating. Counterparties to our derivative financial instruments are limited to major financial institutions with at least a Standard & Poor's and Moody's long-term debt rating of A-/A3. While we do not require collateral or other security to be furnished by the counterparties to our derivative financial instruments, we minimize exposure to credit risk by dealing with a diversified group of major financial institutions and actively monitoring outstanding positions. Concentrations of credit risk with respect to trade accounts receivable are generally limited due to our large number of customers and their diversity across many geographic areas. A portion of our trade accounts receivable outside the United States, however, include sales to government-owned or supported healthcare systems in several countries that are subject to payment delays, particularly in Spain and Italy. Payment is dependent upon the financial stability of those countries' national economies and the creditworthiness of those countries' national governments. We routinely evaluate all government receivables for potential collection risks associated with the availability of government funding and reimbursement practices. We believe the current reserves related to these receivables are adequate and that this concentration of credit risk will not have a material adverse impact on our financial position or liquidity. Our aggregate accounts receivable, net of the allowance for doubtful accounts, in Spain and Italy at December 26, 2014 were \$262 million, of which \$15 million were over 365 days past due. At September 26, 2014, accounts

receivable, net in Spain and Italy were \$256 million, of which \$16 million were over 365 days past due.

38

Contingent Consideration

In connection with an acquisition, we may be required to pay future consideration that is contingent upon the achievement of certain milestones, such as revenue, regulatory or commercialization. As of the acquisition date, we record a contingent liability representing the estimated fair value of the contingent consideration we expect to pay. We remeasure this liability each reporting period and record the change in fair value in our consolidated statement of income. An increase or decrease in the fair value can result from changes in the timing, expected probability and/or amount of revenue estimates or changes in the expected probability and/or timing of achieving regulatory, commercialization or other milestones, as well as changes in discount rates and periods, among other factors. During the first quarter of fiscal 2014, we recorded income totaling \$26 million, which resulted from a reduction in the fair value of our contingent consideration liability associated with our fiscal 2012 acquisition of Maya Medical. No income or expense was recorded during the first quarter of fiscal 2015.

Critical Accounting Policies and Estimates

The preparation of our condensed consolidated financial statements in conformity with U.S. GAAP requires management to use judgment in making estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosure of contingent assets and liabilities.

We believe that our accounting policies for revenue recognition, goodwill, other intangible assets, contingent consideration, other contingencies, pension benefits, guarantees and income taxes are based on, among other things, judgments and assumptions made by management that include inherent risks and uncertainties. There have been no significant changes to the above critical accounting policies or in the underlying accounting assumptions and estimates used in such policies from those disclosed in our annual consolidated financial statements and accompanying notes included in our Annual Report on Form 10-K filed for the fiscal year ended September 26, 2014.

Recently Issued Accounting Pronouncement

In May 2014, the Financial Accounting Standards Board issued updated revenue recognition guidance to clarify the principles for recognizing revenue from contracts with customers. The guidance requires an entity to recognize revenue in an amount that reflects the consideration to which an entity expects to be entitled in exchange for the transfer of goods or services to customers. The guidance also requires expanded disclosures relating to the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. In addition, qualitative and quantitative disclosures are required about customer contracts, significant judgments and changes in judgments, and assets recognized from the costs to obtain or fulfill a contract. This accounting guidance is effective for Covidien beginning in the first quarter of fiscal 2018 using one of two prescribed retrospective methods. Early adoption is not permitted. We are currently assessing the impact of this revenue recognition guidance on our consolidated financial statements.

FORWARD-LOOKING STATEMENTS

We have made forward-looking statements in this report that are based on our management's beliefs and assumptions and on information currently available to our management. Forward-looking statements include information concerning our possible or assumed future results of operations, business strategies, financing plans, competitive position, potential growth opportunities, potential operating performance improvements, the effects of competition, and the effects of future legislation or regulations. Forward-looking statements include all statements that are not historical facts and can be identified by the use of forward-looking terminology such as the words "believe," "expect," "plan," "intend," "anticipate," "estimate," "predict," "potential," "continue," "may," "should" or the negative of these terms or expressions.

Forward-looking statements involve risks, uncertainties and assumptions. Actual results may differ materially from those expressed in these forward-looking statements. You should not put undue reliance on any forward-looking statements.

The risk factors discussed in "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended September 26, 2014 and in this Quarterly Report could cause our results to differ materially from those expressed in forward-looking statements. There may be other risks and uncertainties that we are unable to predict at this time or that we currently do not expect to have a material adverse effect on our business. We expressly disclaim any obligation to update these

forward-looking statements other than as required by law.

39

Item 3. Quantitative and Qualitative Disclosures about Market Risk

Refer to “Part II. Item 7A. Quantitative and Qualitative Disclosures About Market Risk” in our Annual Report on Form 10-K for the fiscal year ended September 26, 2014 for a discussion of our exposures to market risk.

Subsequent to the end of the quarter, we terminated the interest rate swaps that converted \$500 million principal amount of our 3.20% senior notes due 2022 and \$500 million principal amount of our 2.95% senior notes due 2023 from fixed-rate debt to variable-rate debt. There have been no other material changes in the information reported since the fiscal year ended September 26, 2014.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures designed to ensure that information required to be disclosed in reports filed under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the specified time periods, and that such information is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in the Securities Exchange Act of 1934

Rules 13a-15(e) or 15d-15(e)) as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of that date, our disclosure controls and procedures were effective.

Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting during the quarter ended December 26, 2014 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

We are subject to various legal proceedings and claims, including patent infringement claims, products liability matters, environmental matters, employment disputes, contractual disputes and other commercial disputes, as described in our Annual Report on Form 10-K for the fiscal year ended September 26, 2014. Other than described below or in note 14 to our unaudited condensed consolidated financial statements contained in Part I, Item 1 of this Quarterly Report, which is incorporated herein by reference, there were no material developments during the quarter ended December 26, 2014 related to previously described legal proceedings.

Settlement of Certain Litigation

As previously disclosed in Part I, Item 3, pages 22 and 23 of our Annual Report on Form 10-K for the fiscal year ended September 26, 2014, putative shareholder class action complaints have been filed in the United States District Court for the District of Massachusetts by purported shareholders of Covidien under the captions *Taxman v. Covidien plc, et al.*, 14-cv-12949, *Lipovich v. Covidien plc, et al.*, 14-cv-13308 and *Rosenfeld Family Foundation v. Covidien plc, et al.*, 14-cv-13490. On October 20, 2014, the plaintiff in the Rosenfeld action and another purported shareholder of Covidien filed a motion seeking to consolidate the Taxman, Lipovich and Rosenfeld actions, and on November 14, 2014, the United States District Court for the District of Massachusetts granted that motion consolidating the actions (the "Consolidated Action").

On December 23, 2014, the defendants reached an agreement in principle with plaintiffs in the Consolidated Action, and that agreement is reflected in a memorandum of understanding. In connection with the settlement contemplated by the memorandum of understanding, Covidien agreed to make certain additional disclosures related to the proposed transaction with Medtronic, which are contained in Covidien's Current Report on Form 8-K filed on December 23, 2014. The memorandum of understanding contemplates that the parties will enter into a stipulation of settlement. The stipulation of settlement will be subject to customary conditions, including court approval. In the event that the parties enter into a stipulation of settlement, a hearing will be scheduled at which the United States District Court for the District of Massachusetts will consider the fairness, reasonableness, and adequacy of the settlement. If the settlement is finally approved by the court, it will resolve and release all claims in all actions that were or could have been brought by Covidien shareholders challenging any aspect of the proposed transaction, the negotiation or consideration of the Transaction, the Transaction Agreement, dated as of June 15, 2014, by and among Medtronic, Covidien, Kalani I Limited (since renamed Medtronic Holdings Limited), Makani II Limited, Aviation Acquisition Co., Inc., and Aviation Merger Sub, LLC, and any disclosure made in connection therewith, including in the Definitive Joint Proxy Statement/Prospectus, pursuant to terms that will be disclosed to shareholders prior to final approval of the settlement, except that the released claims will not include the claims currently asserted in *In re Medtronic, Inc. Stockholder Litigation*, 27-CV-14-11452, in the District Court, Fourth Judicial District of Hennepin County, Minnesota or the claims currently asserted in *In re Medtronic, Inc. Derivative Litigation*, 14-cv-3540, in the United States District Court for the District of Minnesota described on pages 157 and 158 of the Definitive Joint Proxy Statement/Prospectus. In addition, in connection with the settlement, the parties contemplate that the parties shall negotiate in good faith regarding the amount of attorneys' fees and expenses that shall be paid to plaintiffs' counsel in connection with the actions. There can be no assurance that the parties will ultimately enter into a stipulation of settlement or that the United States District Court for the District of Massachusetts will approve the settlement even if the parties were to enter into such stipulation. In such event, the proposed settlement as contemplated by the memorandum of understanding may be terminated.

Other Legal Proceeding Regarding the Medtronic Transaction

As previously disclosed in Part I, Item 3, page 22 of our Annual Report on Form 10-K for the fiscal year ended September 26, 2014, a putative shareholder class action complaint was filed on July 2, 2014, in the District Court, Fourth Judicial District, of Hennepin County, Minnesota (the "State Court"), by a purported shareholder of Medtronic under the caption *Merenstein v. Medtronic, Inc., et al.*, 27-CV-14-11452, and on August 21, 2014, a putative shareholder class action complaint was filed in that same court by a purported shareholder of Medtronic under the caption *Steiner v. Richard H. Anderson, et al.*, 27-CV-14-14420, which actions were later consolidated together with all cases subsequently filed or transferred into State Court into a single action under the caption *In re Medtronic, Inc.*

Stockholder Litigation, 27-CV-14-11452. On September 30, 2014, the plaintiffs in the consolidated action filed a consolidated amended class action complaint challenging certain transactions to be taken by Medtronic in connection with the proposed acquisition of Covidien by Medtronic, and on October 10, 2014, the defendants moved to dismiss such complaint.

On December 5, 2014, the plaintiffs in the consolidated State Court action filed a motion for a preliminary injunction seeking to, among other things, enjoin the defendants from effectuating the acquisition in the absence of additional disclosure

prior to the Medtronic shareholder vote. On December 30, 2014, a hearing was held in the State Court on plaintiffs' motion for preliminary injunction and on defendants' motion to dismiss. On January 2, 2015, the State Court denied the plaintiffs' motion for preliminary injunction and on January 5, 2015 issued its opinion.

Item 1A. Risk Factors

There have been no material changes to the risk factors disclosed in our Annual Report Form 10-K for the fiscal year ended September 26, 2014. Please refer to the "Risks Factors" section in our Annual Report for a discussion of risks to which our business, financial condition, results of operations and cash flows are subject.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Issuer Purchases of Equity Securities

We did not purchase any ordinary shares under our \$3.0 billion share repurchase program during the first quarter of fiscal 2015.

Item 6. Exhibits

Exhibit
Number Exhibit

31.1 Certification by the Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith).

31.2 Certification by the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith).

32.1 Certification by the Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (filed herewith).

101 The following materials from the Covidien plc Quarterly Report on Form 10-Q for the quarterly period ended December 26, 2014 formatted in Extensible Business Reporting Language (XBRL): (i) the Condensed Consolidated Statements of Income, (ii) the Condensed Consolidated Statements of Comprehensive Income, (iii) the Condensed Consolidated Balance Sheets, (iv) the Condensed Consolidated Statement of Shareholders' Equity, (v) the Condensed Consolidated Statements of Cash Flows and (vi) Notes to the Condensed Consolidated Financial Statements.

43

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

COVIDIEN PUBLIC LIMITED COMPANY

By: /s/ Richard G. Brown, Jr.
Richard G. Brown, Jr.
Vice President, Chief Accounting Officer and
Corporate Controller

/s/ Charles J. Dockendorff
Charles J. Dockendorff
Executive Vice President and Chief Financial Officer
(Principal Financial Officer)

Date: January 23, 2015